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ABSTRACT: 
AIM: To assess the performance characteristics of the various eGFR equations based on 
serum creatinine and serum Cystatin C in predicting the measured GFR in renal allograft 
recipients of Indian Subcontinent 
PATIENTS AND METHODS: Renal allograft recipients were studied at 6 months post 
transplant. GFR was measured by 99mTcDTPA scintigraphy (mGFR). Serum CystatinC 
& creatinine were measured. GFR was estimated (eGFR) by various S.Cr based and 
CysC based equations and compared with mGFR using correlation, bias, precision, 
accuracy and kappa statistics for agreement. 
RESULTS: 134 renal allograft recipients (M:F=101:33; age 34.0±11.5years) were 
studied. Mean mGFR was 52.1±22.6ml/min/1.73Sq.m. Overall, the S.Cr-eGFRs 
overestimated GFR [+15to20±25ml/min/1.73Sq.m.] and had poor correlation (ICC=0.0-
0.4), poor accuracy (@30%-35%; @50%-55%) and poor agreement (K= 0.05-0.20; 50-
60% misclassified) with mGFR.  Among them, CG-LWGFR had marginal correlation 
(ICC=0.25-0.35), least bias (+4.0±22.4ml/min/1.73Sq.m) and most accuracy (@30%-
47.8%; @50%-72.1%).  All CysC-eGFRs had better correlation (ICC=0.45-0.50), lower 
bias (-10to+1±20ml/min/1.73Sq.m), higher accuracy (@30%-60%; @50%-80%) and 
better agreement (K=0.25-0.45; 35-40% misclassified) with the mGFR. The Larsson, 
Macissac and MayoClinic CysC GFRs had the best performance characteristics. 
CONCLUSION: In renal allograft recipients, S.Cr-eGFR estimates poorly correlate, 
widely differ and rarely agree with the mGFR, compared to CysC-eGFR. The CysC-
eGFRs by Larsson, Macissac and MayoClinic provide the best GFR estimates. CysC is a 
better predictor of GFR than S.Cr at 6 months post transplantation. 
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INTRODUCTION 
Research in renal transplantation has so far considered one-year acute rejection episodes, 
one-year graft and patient survival as short-term primary outcomes in evaluating 
therapeutic strategies. With recent advances in immunosuppression and care of a 
transplant recipient, the short-term renal transplant outcomes have been remarkably 
excellent. This makes evaluation of newer therapeutic strategies with such outcomes 
difficult. Meanwhile long-term results do not correlate well with these traditional short-
term end-points. Glomerular filtration rate is used as an indicator of renal function 
worldwide. Renal function in the short term has well been related to long term outcomes 
in renal transplantation. This calls for use of Glomerular filtration rate as a significant 
short term transplant outcome for further studies evaluating efficacy of newer therapeutic 
strategies and to identify prognostic indicators. Renal graft function assessment is now a 
primary criterion for evaluation of newer therapeutic interventions in transplantation. 
Assessment of renal function in a transplant recipient has always been a challenge. Most 
of currently existing methods of GFR measurement and estimation are not well validated 
in transplant recipients. Inulin Clearance is considered as goal standard in measurement 
of renal graft function. However, other traditionally accepted reference methods for direct 
measurement of GFR include use of exogenous markers like radiolabeled isotopes (51Cr 
EDTA, 99mTc-DTPA or 125I Iothalamate) and non-radioactive contrast agents 
(Iothalamate or Iohexol). Measurement of GFR in Indian population has been limited to 
the reference methods only as Inulin is currently not available in this country. In view of 
the cumbersome nature of these tests, several mathematical formulae based on 
endogenous markers of GFR such as S. Creatinine and Cystatin C have been developed 
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for prediction of the GFR based on the abovementioned reference methods. However, 
these equations have been shown to have variable performance in various studies in 
transplant population. Among the several equations based on serum creatinine, the 
MDRD (abbreviated) was found to have least bias and best accuracy.  Cystatin C 
estimates of GFR are studied recently and have been found to be precise and accurate 
compared to creatinine based GFR estimates. However, GFR estimates have not been 
well validated in the transplant population in India. Hence, it is important to study the 
various formulae estimates with available reference method for estimation of GFR. 
 
OBJECTIVES  
To study the agreement between GFR estimated by various prediction formulae based on 
Serum Creatinine and Cystatin C with the GFR measured by 99mTc DTPA renal 
scintigraphy among renal allograft recipients. 
To determine which estimated GFR prediction formula predicts GFR measured by 99mTc 
DTPA renal scintigraphy with precision and accuracy in renal allograft recipients. 
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 REVIEW OF LITERATURE 
1.0 GLOMERULAR FILTRATION RATE (GFR):  
The Glomerular Filtration Rate (GFR) is the volume of isosmotic plasma ultrafiltrate 
filtered through the glomeruli in all the nephrons of the functioning kidney(s) or renal 
allograft. It is equal to the sum of the filtration rates in each of the functioning nephrons. 
Therefore, GFR is considered an index of the function of the kidney. It is a function of 
the renal blood flow and the filtration coefficient of the filtration barrier (glomerular 
basement membrane with the endothelial fenestrae and podocyte-slit diaphragms). The 
number of functioning nephrons affects GFR to a certain extent. A reduction in GFR 
implies either progression of the primary disease or the development of a superimposed 
secondary pathology. An increase in GFR, on the other hand, is indicative of 
improvement in renal function, whereas a stable GFR implies stable disease. However, 
there is no absolute correlation between loss of renal mass and loss of renal function. The 
kidney adapts to loss in nephrons by compensatory hyperfiltration and increased solute 
and water reabsorption in the remaining normal nephrons (single nephron GFR). Normal 
GFR in an adult with normal functioning kidneys is related to age, sex, and body size. 
Usually a value of 130 ml/min/1.73Sq.m is considered as normal in young men and 120 
ml/min/1.73 Sq.m in young women. There is an age dependent reduction in GFR. After 
age 20 to 30 years, GFR decreases by approximately 1.0 ml/min/1.73Sq.m /year. 
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2.0 ASSESSMENT OF GFR: 
GFR estimation is important for detection, appropriate classification, management, 
follow up and prognostication of renal disease. The Kidney/Dialysis Outcome Quality 
Initiative (K/DOQI) guidelines1 have published recommendations on classifying patients 
by chronic kidney disease stage based on the estimation of the GFR. There are several 
ways to measure or estimate GFR. GFR can be measured directly or estimated using 
indirect markers.  
 
2.1 DIRECT METHODS:  
The ideal method of directly measuring GFR would be to measure the urinary or plasma 
clearance of an ideal filtration marker. An ideal filtration marker should be  
• Physiologically inert,  
• With a stable concentration in the plasma,  
• Not protein bound in blood,  
• Freely filtered at the glomerulus, 
• Not secreted,  
• Not reabsorbed,  
• Not synthesized and 
• Not metabolized by the kidney.  
The principle behind the direct methods is that the amount of the substance filtered at the 
glomerulus is equal to the amount excreted in the urine. The excreted amount can be 
measured. The abovementioned properties are important for exact measurement of GFR 
using a filtration marker. Any substance used for measuring GFR should fulfill these 
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attributes. Inulin is the closest to the ideal filtration marker. Hence, inulin clearance is the 
gold standard for determination of GFR. However, Inulin is not freely available and 
cannot be used frequently. Accurate determination of the GFR is also possible using the 
clearance of a radiolabelled compound such as radiolabelled Iothalamate (131I), DTPA 
(99mTc), or ethylenediaminetetraacetic acid (51Cr EDTA). Radio contrast agents like 
Iohexol and non-radiolabelled Iothalamate are also useful for this purpose2. The direct 
method is considered as complex, expensive and difficult to perform technique in routine 
clinical practice. Using the Direct methods, measurement error is reported to be around 5 
- 20 % (This can mean 5-20% variation within a single clearance procedure / between 
clearance procedures on different days). This variation is greater in the higher ranges of 
GFR on the absolute scale. Most of these methods are impractical and expensive for use 
on a regular basis.  
 
2.2 INDIRECT METHODS:  
As an alternative, a number of easy-to-use mathematical equations, incorporating 
different anthropometric variables and biological parameters, have been developed to 
predict (‘estimated GFR’), rather than to directly measure GFR (‘measured GFR’). The 
most common methods utilized to estimate the GFR are the creatinine clearance, and 
estimation equations based upon the plasma creatinine concentration, namely the 
Cockcroft-Gault (CG) equation3   and Modification of Diet in Renal Disease (MDRD) 
equations4. The abbreviated MDRD equation (also known as the four-variable MDRD 
equation) is a simplified version, and is being increasingly utilized5. NKF – K-DOQI 
guidelines recommend that GFR should be estimated from prediction equations that take 
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into account the serum creatinine concentration along with age, gender, race, and body 
size It is important to be familiar with the GFR rather than the serum creatinine value 
while managing patients with renal disease.  In adults, the MDRD Study equation and 
Cockcroft-Gault equations are recommended.  In children, the Schwartz formula6 and the 
Counahan-Barratt equations7 are most popular. 
 
2.3 STANDARDIZATION TO BODY SURFACE AREA:  
The basic function of the kidneys is to clear the waste produced by the body. Hence, it is 
necessary to index GFR for a measure of body size in order to compare values of GFR 
between individuals. In the nineteenth century, it became widely accepted that the 
metabolic rate of an animal is closely related to body surface area (BSA) regardless of 
species8. As a result, it was routine practice to index physiological variables to BSA. 
BSA is calculated by a ‘height–weight’ formula derived by Du Bois brothers from 
sophisticated calculations based on measurement of body surface area from 11 
individuals with widely varying body habitus (including one child)9 .  McIntosh et al. 
proposed indexing kidney function to BSA in one of the early papers describing the 
concept of renal clearance10. They proposed 1.73 Sq.m as the index value as this was 
found to be the average calculated BSA of 25-year-old Americans of that time. Though 
BSA calculated from height–weight formulae of adults in most countries are larger or 
smaller than this number, it is important to note that this is an arbitrarily chosen value and 
that the index value should remain constant to facilitate studies that use historical and 
regional comparisons. However, in clinical evaluation and management of a patient, it is 
important to use the estimated GFR (eGFR) which is estimated for the individual 
 15
patient’s BSA rather than the standardized value extrapolated for a 1.73Sq.m BSA. A 
physiologically appropriate index of standardization is probably the Extracellular Fluid 
Volume (ECFV)11. Nevertheless, for most situations where a measure of kidney function 
is required, it is practical to accept the physiological flaws and sacrifice of accuracy for 
simplicity inherent in indexing GFR for BSA.  
 
2.4 GFR ASSESSMENT IN RENAL TRANSPLANTATION:  
In renal transplantation estimation of GFR using serum creatinine has a great 
disadvantage, since massive reductions in GFR at the higher ranges manifest as very 
modest increments in serum creatinine. It is clear that larger numbers estimating a 
physiologically relevant parameter (eGFR) is definitely more useful and easy to 
understand than small numbers that are inversely and nonlinearly related to the relevant 
physiological parameter (serum creatinine in mg/dl or µmol/L). Following up eGFR 
rather than just serum creatinine values helps to detect graft dysfunction and react to the 
same at an earlier stage.  
Over the past two decades, there have been substantial improvements in short-term 
kidney transplant outcome primarily due to advances in immunosuppression, diagnostics 
and therapeutics, understanding of the transplant immunobiology and in overall care of 
the recipient. As the short term end-points like the 1 year acute rejection rates or 1 year 
graft and patient survival are already excellent, our ability to assess the efficacy of newer 
therapeutic strategies using these conventional short-term end points is limited, 
logistically challenging and clinically questionable. Meanwhile, these traditional end-
points have failed to predict long-term survival, which is currently a major challenge in 
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renal transplantation. Short-term end-points that correlate with long-term graft outcome 
such as post-transplant graft function seems to be an attractive alternative end point for 
clinical trials12 , even though its use as a true surrogate marker for allograft loss has been 
disputed13,14 , . Renal allograft function is the primary criterion for the evaluation of novel 
immunosuppressive strategies in several recent studies15,16. Hence, estimating GFR is 
very important in clinical nephrology and transplantation. 
 
3.0 METHODS OF GFR ASSESSMENT: 
3.1 DIRECT METHODS:  
Direct methods include use of exogenous markers like Inulin, 131I Iothalamate, 99mTc 
DTPA, 51Cr EDTA, Iohexol and non-radiolabelled Iothalamate. Table 1 summarizes the 
characteristics of the direct markers of GFR.  
Table 1 Characteristics of commonly used filtration markers: 
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3.1.1 INULIN / POLYFRUCTOSAN CLEARANCE:  
Inulin Clearance is the gold standard method of evaluation of GFR. Inulin is a 5200MW 
polymer of fructose found in tubers like dahlia and chicory. It is an inert compound and is 
readily measured by colorimetric assays. Glucose is also detected in these assays and 
hence should be removed prior to the assay to prevent false positive results.  
Homer Smith17 originally developed the renal clearance method of measuring GFR. 
Patients are studied in the morning after an overnight fast. An oral water load of 10 to 15 
ml /kg body weight is administered prior to infusion and additional water is administered 
throughout the test to ensure a constant urinary flow of 4 ml/min. Inulin is given as a 
constant infusion to achieve steady state concentration in plasma. Once steady state is 
achieved, several timed samples are taken. Ideally, the bladder needs catheterization. 
Serial plasma levels are also measured. The amount of inulin filtered at the glomerulus 
equals the GFR multiplied by the plasma inulin concentration (i.e., GFR × Pin). The 
amount of excreted inulin equals the urine inulin concentration (Uin) multiplied by the 
urine flow rate (V, volume excreted /unit time). Since              
filtered inulin  =  excreted inulin  
GFR X Pin =  Uin X V  
GFR   =  (Uin × V)/Pin  
The term (Uin × V)/Pin is defined as the clearance of inulin and is an accurate estimate of 
GFR. The inulin clearance, in ml/min, refers to the volume of plasma per unit time that is 
cleared of inulin by renal excretion. Since inulin is only filtered and neither secreted nor 
reabsorbed, all the inulin excreted is all the inulin that is filtered. This means the rate of 
inulin excretion is equal to the rate of inulin filtration. Therefore, the volume of plasma 
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cleared off inulin per unit time therefore indicates the volume of plasma that is filtered 
per unit time, which by definition is the GFR. Usually an average of three to five separate 
determinations has to be made.  However, each of these measurements is subject to 
inaccuracies. The coefficient of variation between clearance periods is 5-10% and the 
coefficient of variation of inulin clearance measured on different days on the same 
individual is approximately 7.5%18. 
To avoid problems related to urine collection, many investigators have tested plasma 
clearance techniques. Plasma clearance of inulin can be measured with the use of either a 
constant infusion or a bolus injection19. If during a constant infusion both the distribution 
space and the plasma level of inulin are constant, the rate of infusion is equal to the rate 
of elimination. The inulin clearance therefore will be equal to the rate of infusion divided 
by the plasma concentration. There is a high degree of correlation between results from 
this technique and those from the renal clearance method19. However, maintaining 
constant plasma concentrations is subject to inaccuracies20 and also very difficult21. 
Hence, the constant infusion technique is rarely used. 
The measurement of GFR using a single injection technique is based on assumptions of 
critical importance. At any time, the quantity of indicator excreted by the kidney is d Q = 
GFR · C ( t ) d t where C ( t ) is the plasma concentration of the indicator at time t . When 
the all the marker injected ( Q 0 ) has been excreted by the kidney, this equation gives: 
GFR = 
Q0
—————∞
0
C(t) dt
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where the denominator represents the area under the plasma concentration–time curve. 
An accurate measurement of this parameter requires a large number of blood samples. 
Mathematical models have been developed to describe the decline of the marker plasma 
levels over time using a limited number of samples. All the models used to estimate 
plasma clearance assume that the volume distribution of the marker and its renal 
excretion are constant over time. One- and two-compartment models have been used to 
calculate GFR.  
 
Figure1.  The top panel represents a two-compartment model. The bottom panel shows 
a typical plasma disappearance curve after single intravenous injection of a marker of 
GFR. This curve can be expressed as a double exponential function. The first 
exponential corresponds to the marker equilibration between compartments 1 and 2, 
and the second function corresponds to the renal elimination phase. The straight lines 
represent the least-square best fit with slopes a and b, respectively. In a one-
compartment model, the hatched area is not considered for calculating the GFR. 
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The plasma disappearance curve of the indicator can be fitted by the sum of two 
exponential functions of the form C = A e − at + B e − bt 
This means that when plasma concentration is plotted on a logarithmic scale against time 
this curve appears as the sum of two straight lines with different slopes. These values can 
be substituted in the above equation to obtain the GFR:  
GFR = Q 0 / [( A / a ) + ( B / b )]. 
In the two-compartment model, both slopes are used to calculate the area under the curve 
and the GFR. The first compartment can be thought of as the plasma pool and the second 
one as the extracellular fluid. Although the two-compartment model is oversimplified, 
since it assumes that the indicator distributes between only two pools, it still requires 
frequent plasma sampling. In this model, the first exponential corresponds to the 
equilibrium of the indicator between the two compartments and the second one represents 
its renal excretion.  
In the one-compartment model, only the data obtained during the elimination phase are 
used to calculate the second exponential and the GFR. This phase generally begins 120 
min after injection. Since, in the one-pool system, the area under the curve is 
approximate, a correction is applied to obtain the GFR value. To ensure accurate 
measurements, multiple samplings are required to get the regression line during the 
elimination phase. Ideally, the higher the sample number the most accurate the value of 
the regression line and the calculation of the GFR. Alternatively, methods based on a 
single blood sample obtained between 60 and 240 min after injection can also be used. 
These techniques can give a reasonable estimate of the GFR. Nevertheless, multiple 
sampling yields a more accurate determination of GFR. Four samples drawn every hour 
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from 2 to 5 h after the indicator injection are enough in patients with normal or slightly 
decreased renal function (usually serum creatinine < 130 μM). When the decline of the 
GFR is more pronounced, the sampling time must be adapted. In these cases, samples 
obtained as late as 24 h after injection are suitable.  
Another limitation to the use of plasma clearance technique is the presence of a third 
compartment. For example, in patients with ascites the assumptions made to calculate the 
GFR from a one- or a two-compartment model are not met, so other mathematical models 
should be used 
Thus, a number of problems limit the usefulness of inulin clearance as a marker of GFR. 
Although most data indicate that inulin is freely filtered and is not handled by the renal 
tubules, this indication may not be true for all clinical situations. For example, impaired 
filtration, back-diffusion of inulin, or both can limit the usefulness of this marker in 
kidney transplant recipients22 . These logistic reasons along with the high cost and lack of 
availability have made inulin clearance at best a research tool rather than a clinical test.  
The other substance that comes close to Inulin is polyfructosan. Nowadays the 
polyfructosans (Inutest® or Sinistrin®) are preferred to inulin since they are easily 
soluble in water at room temperature. These substances are not endogenously present in 
humans and must be intravenously infused throughout the GFR measurement. In practice, 
after a bolus injection, the dose of which is calculated according to the patient's body 
weight, the marker is infused at a constant rate to obtain a stable plasma concentration. 
This is achieved within 1h. To ensure a urine flow rate above 2 ml/min throughout the 
investigation, the patients are hydrated with an oral water load, and additional water is 
given periodically. Once the steady state for plasma marker concentration has been 
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achieved, the patients are asked to empty their bladder completely and several urine 
samples are collected at regular intervals (generally 30 or 60 min). The indicator plasma 
concentration is serially measured either at the middle or at the beginning and at the end 
of each period of urine collection. To minimize error, an average of three to five 
determinations are made. Polyfructosan and inulin determinations in the plasma are based 
upon hydrolysis of the polymer and measurement of the resultant free fructose with 
colorimetric assay. High-performance liquid chromatography (HPLC) techniques can 
also be used. Glucose may interfere with the colorimetric dosages, so plasma samples 
should be treated with glucose oxidase whenever plasma glucose concentrations are 
above 10 mM. The coefficient of variation of Polyfructosan or inulin clearance between 
consecutive periods or between measurements on different days is about 7%18. This 
means that for an initial GFR value of 40 ml/min, a variation of 6 ml/min in a subsequent 
investigation predicts a real modification of GFR at an alpha error less than 5%. 
 
3.1.2 IOTHALAMATE CLEARANCE :   
125 I-iothalamate is a high osmolar ionic radiocontrast agent, in which 127 I has been 
replaced by its isotope 125 I. Its MW is 614 Da. The relatively long half-life of 125 I (60 
days) makes it easy to use. The main advantages of the radiolabelled indicators are the 
ease and the accuracy of measurements. Their drawback is the delivery of radioactivity. 
In adults, the total dose delivered is less than the amount received during standard X-ray 
procedures. However, these radioisotopes are excreted and concentrated in urine, 
exposing the bladder and the gonads to higher levels of radiation. Furthermore, in many 
patients, the measurement of GFR is controlled repeatedly throughout their lifetime 
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increasing the cumulative dose irradiation. The use of these radioactive markers is also 
problematic in women before menopause, since in most cases the physician cannot be 
sure that they are not pregnant. Similarly, the use of radioisotope in children should be 
avoided. In Europe and the United States, the regulatory agencies maintain a strict control 
over the storage, the dispensation, and the disposal of radioactive products and the use of 
isotopes is limited to specific departments.  
To avoid using radiolabelled compounds, several techniques have been developed 
especially to measure non-radioactive radio-contrast agent concentration in plasma. Two 
molecules have been used: Iothalamate sodium, and more recently, Iohexol (omnipaque), 
which has become the most popular non-radioactive marker used to calculate GFR with 
the plasma clearance technique. Iothalamate estimation by HPLC is an alternative to 
radionuclide isotope method.  
Renal clearance studies with Iothalamate has been shown to correlate well with GFR in 
most studies 2, 23 -26 ,,,. Standard renal clearance of Iothalamate using constant infusion to 
achieve steady state in blood can be considered as a relative gold standard technique of 
GFR estimation in the absence of Inulin. However, with a non renal correction factor of 
nearly 10ml/min/1.73sq.m, estimates of GFR by renal clearance with steady state 
infusion method and bolus injection method are comparable and the latter method is both 
precise and unbiased. Plasma clearance of Iothalamate is less accurate and overestimates 
GFR by about 3-10 ml/min/1.73sq.m27.. Subcutaneous infusion methods have also been 
standardized in children for GFR estimation28  .  
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3.1.3 DTPA CLEARANCE:   
DTPA is an 110MW substance which can be tagged with Technetium radioisotope 
(99mTc) for use in nuclear medicine. GFR can be estimated either by a standard renal 
clearance or plasma clearance method or using the Renal Scintigraphy. The plasma 
clearance method is performed from whole plasma. However, in view of variable protein 
binding in hypoalbuminemia, which is frequently observed in the malnourished renal 
patient, it can also be performed from the protein-free ultra filtered plasma (PFP).  
Several methods of plasma clearance have been described. A comparative analysis29  
revealed that the two-sample plasma method of Russell and the urinary method of 
Jackson were the most accurate methods overall. The one-sample plasma method of 
Russell, the volume of distribution method of Fawdry, and a terminal slope method were 
less reliable, especially at low (0-60 ml/min) GFR. The Russell two point GFR and 
Jackson urinary GFR can be used as complementary techniques and are recommended as 
primary methods of DTPA GFR determination. Unlike the renal or plasma clearance 
techniques, in 99mTc-DTPA renography, the GFR is calculated without blood or urine 
sampling30 . Several techniques have been applied in clinical practice, because of 
technical simplicity and requirement for less time for the patients. The method introduced 
by Gates31  has been most common in the routine setting. When compared to the plasma 
clearance methods, the renal uptake method of Gates correlated poorly to the standards at 
all GFR levels even when corrected for body surface area or blood volume. In addition, 
Gates' method severely overestimated GFR in children32 . Several modifications such as 
depth correction, use of dual gamma camera for scintigraphy and calculating geometric 
mean instead of arithmetic mean, have been reported 33  to improve the accuracy of the 
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gamma camera method for estimation of GFR. Although the diagnostic accuracy of the 
gamma camera methods is debated 34-37  ,,,, the program is provided as a software package 
by manufacturers in commercially available computer systems dedicated for nuclear 
medicine. In addition, this method does not require sampling blood or urine for 
assessment of GFR. In spite of the shortcomings, the gamma camera method is still used 
widely in the clinical situation to assess GFR in many centers.  
 
3.1.4 EDTA CLEARANCE:  
Ethylenediaminetetraacetic acid (EDTA), a 292 MW substance with minimal protein 
binding capacity, when tagged with radioactive Chromium 51Cr can be used for 
estimating GFR. It can be used with continuous infusion or bolus injection with single or 
multiple sampling methods for renal or plasma clearance methods for GFR measurement. 
51Cr EDTA is regarded as the standard radiopharmaceutical for routine GFR 
measurement in Europe. 51Cr EDTA clearance from a single injection emerged as an 
adequate simpler technique in the early ‘70s38 . GFR was calculated from the area under 
the plasma clearance curve, which required multiple blood samples to be taken over a 
period of several hours (Radio decay method). Although simpler than inulin infusion, it 
was still labor intensive and the technique was further simplified by restricting the blood 
sampling to the second of the two exponential components of clearance39  (Slope-
Intercept method). This simplification introduced systematic errors in the values of GFR 
obtained and various methods of correction have been derived40 . The methodology 
underwent even further simplification by reducing the number of samples to one41 . 
Empirical relationships between the apparent volume of distribution and GFR were 
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derived which allow GFR to be estimated from a single sample concentration with 
reasonable precision42 . There are several systematic errors between the techniques. The 
DTPA clearance is systematically higher than that of EDTA43 . EDTA plasma clearance 
is lower than inulin clearance. Urine clearance of EDTA is systematically less than that 
of plasma clearance44 . The precision of EDTA clearance is more in range of normal GFR 
and hence it is useful for detection of hyperfiltration.  
 
3.1.5 IOHEXOL CLEARANCE:  
Iohexol (Omnipaque) is a 821 MW non ionic x-ray contrast medium of low osmolality 
that is extensively used in clinical radiology. It does not bind to serum proteins and is 
100% filtered through glomerulus, with no indications of tubular secretion or 
reabsorption45 . A good agreement was reported between the urinary clearance of inulin 
and the total body clearance of Iohexol over a wide range of GFR values46   (6–160 
ml/min/1.73sq.m.). Iohexol is measured by several methods such as HPLC (UV)47 , 
capillary electrophoresis48 , atomic spectroscopy49  , chemical measurement (iodine), X-
ray absorption and radionuclide scintigraphy.  HPLC is commonly used for estimating 
the levels in plasma. It is extensively used in Sweden (>8000 GFR estimations)50 . There 
is a strong concordance with inulin clearance. The Multiple sample method has fewer 
errors than single sample method.  
 
3.1.6 CREATININE CLEARANCE:  
Unlike the substances described until now Creatinine, a 113 MW substance is an 
endogenous marker of GFR. Creatinine is derived from the metabolism of creatine in 
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skeletal muscle51  and from dietary meat intake52 . Its production is reduced in liver 
disease53 . It is released into the circulation at a relatively constant rate and has a stable 
plasma concentration. Creatinine is freely filtered across the glomerulus and is neither 
reabsorbed nor metabolized by the kidney. Hence, it is used as an endogenous marker. 
However, approximately 15 % of urinary creatinine is derived from tubular secretion 
through the organic-cation secretory-pathways in the proximal tubule54  and this value 
may increase in settings of renal failure. The effect of secretion is usually ignored for 
day-to-day use. Then, all of the filtered creatinine (product of the GFR and the plasma 
creatinine concentration [PCr]) will be excreted (product of the urine creatinine 
concentration [UCr] and the urine flow rate [V]). Thus: 
   GFR x PCr = UCr x V  
   GFR    =    [UCr x V]/PCr  
This formula is more aptly called the creatinine clearance and tends to exceed the true 
GFR by the 10 to 15 % (due to the excess 10-15% of urinary creatinine that is derived 
from tubular secretion)55 . Fortunately, this error is balanced by an error of almost equal 
magnitude in the measurement of the PCr in the laboratory. The creatinine clearance is 
usually determined from a 24-hour urine collection. Shorter collections tend to give less 
accurate results. The normal value for the creatinine clearance is 95 ± 20 ml/min in 
women and 120 ± 25 ml/min in men. However, creatinine clearance exceeds Inulin 
clearance at low GFR in view of tubular secretion. There is also a mild increase in extra – 
renal clearance of creatinine 51. The ratio of urinary creatinine clearance to urinary inulin 
clearance may vary from 1.14 to 2.27 in different subjects.  
 28
 
FIGURE 2. Comparison of the clearance of creatinine and inulin measured in 144 
patients with normal or impaired glomerular filtration rate (Prié and Friedlander, 
unpublished data). Panel (a) shows the correlation of the two methods of 
measurement. Panel (b) shows the agreement of the two methods of measurements 
The major errors limiting the accuracy of the creatinine clearance are: 
• An incomplete urine collection 
• Increasing creatinine secretion 
An incomplete urine collection: The completeness of the collection can be estimated 
from knowledge of the normal rate of creatinine excretion (which is equal to creatinine 
production in the steady state). In adults under the age of 50, daily creatinine excretion 
 29
should be 20 to 25 mg/kg (177 - 221 µmol/kg) of lean body weight in men and 15 to 20 
mg/kg (133 - 177 µmol/kg) of lean body weight in women. From the ages of 50 to 90, 
there is a progressive decline in creatinine excretion to 50 % (to about 10 mg/kg in men), 
primarily due to a fall in muscle mass. 
 
Increasing creatinine secretion: The accuracy of the creatinine clearance is also limited 
by the fact that enhanced creatinine secretion limits the rise in PCr when the GFR falls 56 . 
This secretory capacity is also not uniform. For example, when the GFR falls to a range 
of 40 to 80 ml/min (as measured by alternative modalities), the absolute amount of 
creatinine secreted can rise by more than 50 %, accounting for as much as 35 % of 
urinary creatinine 24. Thus, creatinine excretion is much greater than the filtered load, 
resulting in a potentially large overestimation of the GFR. The net effect is that the 
creatinine clearance may be normal (>90 ml/min) in about one-half of patients with a true 
GFR of 61 to 70 ml/min and one-quarter of those with a true GFR of 51 to 60 ml/min57 . 
Some patients with advanced disease have a creatinine clearance that exceeds the GFR by 
more than twofold. Thus, creatinine clearance represents an upper limit of what the true 
GFR may be.  
 
Drugs like trimethoprim and cimetidine compete and block the pathways of creatinine 
excretion in the renal tubules.  Oral administration of Cimetidine at a dose of 400mg BD 
to a total cumulative dose of 1200mg, results in complete blockade of the tubular 
secretion of creatinine in most patients. Thus the creatinine that is excreted is derived 
exclusively from the glomerular filtration58, 59 , . These methods improve the accuracy 
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(bias and precision) of creatinine clearances60, 61 ,  . However, some subjects required 
relatively large doses for complete inhibition of renal tubular secretion of creatinine. 
In early renal disease when the GFR is still near normal, an initial decline in GFR may 
lead to only a slight increase in the serum creatinine (S.Cr) (0.1 to 0.2 mg/dl [9 to 
18µmol/L]). This is because of an increase in proximal tubular creatinine secretion. The 
net effect is that patients with a true GFR as low as 60 to 80 ml/min (as measured by the 
clearance of a true filtration marker such as inulin, Iothalamate or DTPA) may still have a 
S.Cr that is 1.0 mg/dl (88 µmol/L)62  . Thus, a relatively stable S.Cr in the normal or 
near-normal range does not necessarily imply that the disease is stable. However, once 
the S.Cr exceeds 1.5 to 2 mg/dl (132 to 176 µmol/L), the secretion is effectively 
saturated. Hence, a stable value above that usually does represent a stable GFR.  
Limited data also suggests that tubular secretion is significant in patients with the 
nephrotic syndrome. In one study based upon a determination of GFR by inulin 
clearance, decreased serum albumin levels were associated with a marked increase in 
tubular creatinine secretion (36 ml/min /1.73 Sq.m for nephrotic patients with serum 
albumin levels less than 2.6 g/dl versus 11 ml/min /1.73 Sq.m for normal controls)63  .  
The degree of creatinine secretion may vary with time, affecting the S.Cr independent of 
the GFR. In effectively treated lupus nephritis, for example, a rise in the GFR may not be 
accompanied by the expected reduction in the S.Cr due to a fall (via an uncertain 
mechanism) in creatinine secretion64 . In this setting, decreased activity of the urine 
sediment, diminished protein excretion, and lack of further elevation in the S.Cr all point 
toward possible improvement. 
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There are certain settings in which there may be an acute increase in creatinine 
production. One example is a recent meat meal. In addition, it has been suggested that the 
S.Cr rises more rapidly with rhabdomyolysis (up to 2.5 mg/dl or 220 µmol/L /day) than 
with other causes of acute renal failure65 . 
The presence of certain drugs may increase the plasma level of the serum creatinine by 
decreasing creatinine secretion. This includes trimethoprim (most often given in 
combination with sulfamethoxazole) and the histamine 2-blocker cimetidine, which result 
in a self-limited and reversible rise in the S.Cr of as much as 0.4 to 0.5 mg/dl (35 to 44 
µmol/l). Certain substances may interfere with the plasma assay; thereby artifactually 
increasing the S.Cr Value. 
Direct Clearance methods thus provide an acceptable measure of GFR, though there is a 
tendency to overestimate GFR by about 3.5-8ml/min/1.73sq.m. However, the procedure 
is cumbersome and costly for routine clinical use. However, it may be of value in certain 
clinical situations such as: 
1. Extremes of body size  
2. Extremes of age (low BMI for MDRD formula)  
3. High or low dietary intake of creatinine (dietary supplements, 
vegans/vegetarians)  
4. Patients with muscle diseases or atrophy (muscular dystrophy, amputation, 
paralysis, malnutrition)  
5. Particular ethnic groups (Aborigines, Pacific Islanders, Indo-Asians) 
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3.2 INDIRECT METHODS:  
For many years, the physicians have been seeking for an endogenous marker, the plasma 
concentration of which would be related to the renal filtration levels and would be readily 
measured. For this purpose, three molecules have been used: urea, creatinine, and CysC.  
 
3.2.1 Urea:  
Urea was the first described marker of renal function. Even today renal failure is still 
referred to as uremia. Urea is a small molecule (60MW) derivative of nitrogen 
metabolism in the liver. Daily urea production varies not only with protein intake but also 
dependent on intestinal protein breakdown. Conditions where intestinal protein 
catabolism is high, such as gastrointestinal bleeding, Plasma Urea levels are elevated 
even with normal renal function66 . Urea is freely filtered by the glomeruli. However, it is 
easily reabsorbed by the tubules, mostly in PCT, in parallel with Na and water 
reabsorption. Hence, several factors (apart from decreased GFR) modify plasma urea and 
urea renal excretion67 . In conditions when water and sodium reabsorption is elevated, 
such as in hypovolemia or hypotension, urea reabsorption is augmented leading to high 
urea serum concentration (pre renal azotemia). Adversely, liver diseases reduce urea 
plasma levels. For these reasons, plasma urea cannot be used for the assessment of the 
GFR68 .  
 
3.2.2 Creatinine:  
Serum creatinine concentration (S.Cr) is dependent on GFR and was first employed as a 
marker of GFR in clinical medicine69  in early ‘20s. Creatinine excretion (GFR x S.Cr) 
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equals creatinine production in the steady state and that creatinine production is relatively 
constant. Thus   GFR x S.Cr    = constant. Thus, the plasma creatinine concentration 
varies inversely with the GFR (Figure 3.) If, for example, the GFR declines by about 
50%, the creatinine excretion will initially be reduced, leading to creatinine retention and 
a rise in the S.Cr until the latter has doubled. At this point, the filtered load will again be 
equal to excretion:  
GFR/2 x 2 S.Cr    = GFR x S.Cr    = Constant 
 
Figure 3. Relationship between plasma creatinine and GFR. 
A rising S.Cr implies disease progression, a falling level indicates improvement, and a 
stable value usually reflects stable disease. Nevertheless, there are several factors that 
might influence plasma creatinine (see Table 2) 
Based on the third National Health and Nutrition Examination Survey, among individuals 
without hypertension or diabetes in the United States, the mean S.Cr values for men and 
women70   were 1.13 and 0.93 mg/dl (100 and 82 µmol/L), respectively. There are several 
limitations with plasma creatinine values.  
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Table 2. Factors affecting the Serum creatinine levels 
 
The Jaffe’s alkaline picrate method (colorimetric) of S.Cr assay recognizes non-
creatinine chromogens (e.g. acetoacetate)71 , thereby falsely elevating S.Cr values by ≥ 
0.5 - 2 mg/dl. Modern auto analyzers use S.Cr assays with less interference by 
chromogens (e.g., kinetic alkaline picrate or enzymatic methods, such as the 
imidohydrolase method). Laboratories with calibration differences can provide varying 
S.Cr measurements that can lead to erroneous estimations of GFR in patients with 
relatively normal S.Cr72 . Differences in method and equipment may also affect creatinine 
measurement. 
2
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Figure 4. The Creatinine Standardization Program, Canada. 107 laboratories, which 
tested creatinine on 124 analyzers from six different manufacturers, were analyzed. 
The percentage total error for the measurement of creatinine (98.9 µmol/L) at baseline 
is depicted as blue bars (ranging from 4 to 54% with an overall average of 23.9%). The 
between-day precision (coefficient of variance) is also plotted (black bars). 
When the S.Cr > 6 mg/dl (530 µmol/L), there is intestinal bacterial overgrowth and 
increased bacterial creatininase activity73 , resulting in increased extra renal creatinine 
clearance, reduction in S.Cr  and overestimation of GFR.  
In summary, S.Cr is affected by the level of GFR and by factors independent of GFR, 
including age, gender, race, body size, and diet, certain drugs, and laboratory analytical 
methods. Therefore, S.Cr is not an accurate index of the level of kidney function, and the 
level of S.Cr  alone should not be used to assess the stage of chronic kidney disease. 
However, since S.Cr can be easily measured routinely, many authors have tried to find 
mathematical formulae taking into account the various causes of variation of serum 
creatinine to deduce the GFR level. 
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The Creatinine Based Estimated GFR formulae:  
Prediction equations for GFR calculation from S.Cr have been developed by several 
authors. There are nearly 45 prediction equations in literature.  
Table 3. Prediction Equations for eGFR based on Serum Creatinine 
 
These equations include variables such as age, sex, race, and body size, in addition to 
serum creatinine, as surrogates for muscle mass, for calculation of GFR. They are all 
derived with the use of regression techniques to model the observed relation between the 
S.Cr and the measured GFR in a study population. However, most of the equations have 
been studied in restricted populations - usually patients with CKD and reduced GFR. 
Hence, evaluation of these equations in other populations is necessary to demonstrate the 
generalizability. A few of these equations are described in detail: 
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1) The Cockcroft-Gault GFR:  
The Cockcroft-Gault formula was originally derived in 249 consecutive hospitalized 
patients (96% male, age range 18–92 years) at the Queen Mary Veterans’ Hospital in 
Canada, based on the means of two 24-hour creatinine clearances3. S.Cr concentrations 
were determined by Jaffé reaction using an auto analyzer (N-11B, Technicon Instruments 
Corp, NY). The Cockcroft- Gault Formula: 
CrCl = {[(140-age) X weight] / (72 X S.Cr)} X (0.85 if female) 
The derived formula was then used to predict creatinine clearance in a validation cohort 
of 236 patients (206 males, mean creatinine clearance 72.7 ± 36.6 ml/min). Mean 
predicted creatinine clearance by the Cockcroft-Gault formula was 75.8 ml/min with an 
R2 of 0.69. Accuracy at ≤35% and ≤20% was observed in 95% and 67% of patients 
respectively. The main limitations of the study were:  
1. The questionable external validity, as the training and validation samples consisted 
predominantly of hospitalized, white men, many of whom did not have CKD. 
Nevertheless, the Cockcroft-Gault formula has been extensively validated and found 
to exhibit satisfactory accuracy in diverse populations including women, various 
ethnic groups, and across a broad range of GFRs. These studies are listed in Table 4. 
2. The formula was originally validated against creatinine clearance, which is known to 
appreciably overestimate inulin clearance and vary from day to day by 10%–20%74 . 
Subsequent validation studies have generally shown equivalent or superior 
performance against a variety of GFR measures (inulin, iothalamate, 51Cr-EDTA, 
DTPA, MAG-III and Iohexol clearances).  
3. The calibration bias of creatinine assay used vs. ‘true’ creatinine was not reported. 
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4. The results of the Cockcroft-Gault formula were not corrected for body surface area. 
Table 4. Studies evaluating the Cockcroft – Gault GFR formula 
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The bias in estimating GFR using the Cockcroft-Gault equation varied markedly across 
studies (from -14% to +25%). The accuracy measures indicated the majority (median of 
75%) of estimated GFRs were within 30% of the measured GFR, an accuracy considered 
sufficient for good clinical decision-making. The Cockcroft-Gault equation does not 
include body size. Some studies have standardized the results for body surface area. 
Other studies have suggested using lean body mass75  rather than total weight, especially 
for obese individuals. 
 
2) Modification of Diet in Renal Disease (MDRD) GFR Formulae:   
The MDRD equation was developed in 1628 CKD patients enrolled in the baseline 
period of the Modification of Diet in Renal Disease (MDRD) study, of whom 1070 were 
randomly selected as the derivation sample and the remaining 558 patients constituted the 
validation sample4. The exclusion criteria for the MDRD study were patients with body 
weight extremes (< 80% or > 160% of standard body weight), dubious compliance, 
insulin-dependent diabetes mellitus or heavy proteinuria (> 10 g/day). GFR was directly 
measured as iothalamate clearance and S.Cr was measured by means of a modified 
kinetic Jaffé reaction using a Beckman Astra CX3 autoanalyzer (Brea, CA). Using 
multiple regression analysis, a 6-variable equation (equation 7 – MDRD 1) was 
developed, which included the variables of S.Cr, age, gender, ethnicity (African-
American or other), serum urea and serum albumin.  The MDRD- 1 equation is: 
MDRD-1 GFR = 170  X  (S.Cr) -0.999  X  age-0.176  X  (Ur X 2.78)-0.17  X  alb0.318        
     X  (0.762 if female)  X  (1.18 if African-American) 
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The equation was validated against GFR corrected for body surface area (BSA) and so, 
unlike the Cockcroft-Gault formula, the predicted GFR is expressed as ml/min/1.73sq.m, 
and does not require subsequent BSA normalization. Compared with the BSA-corrected 
Cockcroft-Gault formula, the MDRD-1 equation was more precise (r2 0.90 vs. 0.84), less 
biased (3% vs. 23%) and exhibited greater accuracy within 30% (91% vs. 65%) and 
within 50% (98% vs. 83%). The accuracy of GFR values was worst for Cockcroft-Gault 
GFR (non- BSA-corrected), intermediate for BSA-corrected GFR, and best for MDRD 
GFR76 . The precision, accuracy and bias of the MDRD GFR has been validated in 5069 
subjects over 16 studies and generally found to be superior to those of the Cockcroft-
Gault formula. 
An abbreviated, 4-variable MDRD equation (age, gender, African-American ethnicity 
and S.Cr) has subsequently been developed (MDRD-2 or Abbreviated MDRD 
Formula). The Abbreviated MDRD Formula for creatinine evaluated by Jaffe method is  
MDRD2 GFR  =  186  X   (S.Cr)-1.154   X   (Age)-0.203    X    (0.742 if female)      
       X  (1.210 if African American) 
However, with recent efforts at standardizing the serum creatinine measurement to avoid 
analytical errors, some laboratories measure S.Cr values standardized to the IDMS 
(isotope dilution mass spectrometry) reference method. A new MDRD 2 formula has 
been developed for use with IDMS traceable S.Cr measurement:  
Std. MDRD2 GFR = 175  X   (S.Cr)-1.154  X   (Age)-0.203  X   (0.742 if female)    
X (1.210 if African American) 
 
The MDRD2 GFR has been validated in 8654 subjects over 13 studies.  
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Table 5. Studies evaluating the MDRD GFR formulae 
 
It was generally found to be comparable to those of MDRD1 GFR and superior to those 
of Cockcroft-Gault GFR.  Several studies have confirmed that the MDRD2 equation 
shows generally greater precision and accuracy than the Cockcroft-Gault formula in 
patients with CKD (GFR < 60 ml/min/1.73 Sq.m)77-79    , but tends to be more biased with 
significant underestimation of measured GFR in patients with normal or near-normal 
renal function80-83    . In view of wide range of applicability, better precision and accuracy 
in lower GFR ranges, The National Kidney Foundation1 and the European Renal 
Association84  have endorsed this formula for diagnosis, classification and management 
of Chronic Kidney Disease.  
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3) Nankivell GFR Formula:  
Nankivell et al (1995) developed a new prediction equation for estimating GFR in renal 
transplant recipients85  based on  a total of 256 randomly selected DTPA GFR 
measurements. Three new formulae were derived and then tested on an independent 
group of randomly selected GFR measurements (n = 255), comparing with the Cockcroft-
Gault, Mawer86 , Hull88 , Jelliffe-188  , and Jelliffe-289   methods. The Formula B was 
found to provide better precision and less scatter and was proposed to replace other 
published formulae for calculating GFR in renal transplant recipients.  
Formula B Nankivell GFR = [6700 / (S.Cr X 88.4)] + (weight/4) - (urea/12)   
– [100/(height)2] + 35 – [10 (if female)] 
The major weakness of this study was that the prediction equations were not tested in a 
large independent cohort, making the external validity of this study questionable.  The 
proportion of predicted GFR differing from inulin clearance by ±10 ml/min/1.73 Sq.m, 
was highest for Nankivell formula compared to MDRD and Cockcroft Gault GFR 
formulae90 . Overall, the current evidence suggests that the MDRD formula is the best 
available equation for estimating GFR in transplant recipients. 
 
4) Mayo Clinic Quadratic GFR Formula:  
Rule et.al. from Mayo Clinic, analyzed a series of 580 potential kidney donors referred to 
the Mayo Clinic and found that the MDRD-2 equation significantly underestimated GFR 
in healthy persons. This led the authors to develop new equations that performed better 
than the abbreviated MDRD formula in healthy persons.  
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Table 6. The Mayo Clinic Quadratic Equation for GFR 
 
In a subsequent study among elderly adults from the community91 , it was found that 
using the MDRD2 equation increased the prevalence of CKD and weakened the 
epidemiologic association between GFR and mortality. However, the Mayo Quadratic 
equation (derived by using healthy persons and patients with chronic kidney disease) 
decreased the prevalence of a CKD and strengthened association with mortality in the 
same population. Hence, the authors concluded that in order to better understand the 
epidemiology of early CKD, Mayo Quadratic GFR may be better than MDRD2. These 
equations however have not significantly outperformed MDRD-2 equation in other 
studies92  and tend to classify more people as suffering from CKD. 
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3.2.3 Cystatin C:  
Cystatin C (CysC) is a 122-amino acid, 13-kDa protein member of cysteine proteinase 
inhibitors. CysC has been suggested to be closer to the “ideal” endogenous marker93   
owing to the several desirable properties:  
1. A constant rate of production by a ‘housekeeping’ gene in all nucleated cells94 ,  
2. Lack of effect of age, gender or muscle mass on CysC production95-97      
3. Free filtration at the glomerulus because of its small size and basic pI (~9.0)98   ,  
4. Complete reabsorption and catabolism by the proximal tubule cells99  , (hence, 
cannot be used for urine clearance techniques) 
5. Lack of renal tubular secretion98,  
6. Lack of reabsorption back into the bloodstream98, and  
7. Minimal or no analytical interference100  . 
The diagnostic value of serum CysC in clinical nephrology was not extensively 
investigated until 1994 because of general difficulties in standardizing immunometric 
methods. More recently, automated homogeneous immunoassays using latex or 
polystyrene particles coated with CysC-specific antibodies have been developed based on 
turbidimetry (particle-enhanced turbidimetric immunoassay, PETIA) 100 or nephelometry 
(particle-enhanced nephelometric immunoassay, PENIA)101  . The PETIA method 
generally produces reference values that are 20%–30% higher than those from the PENIA 
method. A meta-analysis demonstrated that the correlation between GFR and the 
reciprocal of CysC was significantly stronger when CysC was measured by the PENIA 
method (14 studies including 1698 subjects) rather than when it was measured by other 
methods (21 studies involving 1953 subjects)102  . In this meta-analysis (of 54 studies, 
 45
incorporating 4492 subject samples of CysC as a GFR index), it was observed GFR 
correlated significantly better with the reciprocal of CysC (r = 0.816, 95% CI 0.804–
0.826) than with the reciprocal of S.Cr (r = 0.742, 95% CI 0.726–0.758, p < 0.001). Thus, 
CysC was clearly superior to S.Cr as a marker of GFR.  
 
Figure 5. Cystatin C values correlate well with GFR 
However, this finding must be balanced against the potential limitations of the studies of 
CysC as a GFR marker to date, which include  
a. Lack of standardization (differences in antibodies, calibrators & technologies)103  
b. Biological variability of CysC (PETIA104   vs. EIA105 ) – [Variability %: analytical - 
8.9% vs. 8.8%, within-subject - 13.3% vs.15% and between-subjects -8.1% vs. 5.7%.]  
c. Factors influencing CysC levels independent of creatinine clearance such as: age, 
weight106 , gender, CRP level, smoking107 , cyclosporine A108 , corticosteroid 
treatment109  , bronchial asthma110 , thyroid dysfunction111, 112   , physical activity113 , 
certain malignancies114  and pregnancy115  . 
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d. Lack of standardization of statistical analyses,  
e. Absence of wide applicability like MDRD-2 GFR  
The data form the biological variability suggested that CysC may be better at detecting 
the onset of an abnormal GFR than S.Cr, and equally (if not more) sensitive as S.Cr for 
detecting changes in the same individual. The sensitivity of CysC is higher at higher GFR 
ranges compared to S.Cr.  A recent study116 has confirmed that CysC is better predictor of 
longitudinal changes in GFR than S.Cr. (MDRD).  
 
Figure 6. CysC is better predicts longitudinal changes in GFR 
Some studies have shown that CysC may be falsely elevated in renal transplant patients 
leading to a significant underestimation of GFR by 14%–25%117, possibly because of 
interference by immunosuppressive agents: corticosteroids can increase CysC levels 
whereas cyclosporine decreases CysC concentrations. In several studies, CysC levels 
correlated well with mortality118 and cardiovascular risk119.  
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The Cystatin C Based Estimated GFR formulae: 
Several prediction equations for estimating GFR from CysC values have been devised. 
We will discuss a few of them in detail here:  
 
1) Le Bricon GFR 120:  
The formula was derived from a population of 25 renal allograft recipients, who were 
followed up for at least 3 months duration. CysC was measured by the Dade Behring 
PENIA method. Reference GFR was measured by GFR by the reference 51Cr EDTA 
clearance. GFR could be estimated from CysC (in mg/L) according to the following 
formula:  
Le Bricon GFR (ml/min/1.73sq.m) = 78 X (1/CysC) + 4  
Overall, CysC underestimated GFR by 14% with no false negatives.  
 
2) Larsson GFR121:  
This formula was developed separately for the CysC measured by Dade Behring PENIA 
and Dako Cytomation PETIA methods, from 100 patients (adults and children) referred 
to a Swedish center for Iohexol clearance (Reference GFR). The formulae were derived 
to calculate GFR expressed in ml/min: 
Larsson GFR (Dade Behring) = 77.24 X (CysC)-1.2623  
Larsson GFR (Dako Cytomation) = 99.43 X (CysC)-1.5837  
A stronger correlation (p<0.0001) was found between CysC and Iohexol clearance 
(r2=0.91) than between S.Cr and Iohexol clearance (r2=0.84). 
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3) Hoeck GFR122:  
This formula was developed on 123 adult patients (including 30 diabetics) with suspected 
renal disease in Netherlands, comparing the CysC measured by Dade Behring PENIA 
method (in mg/L) to 125I Iothalamate clearance GFR (reference method).  
Hoeck GFR (ml/min/1.73 Sq.m) = [80.35 X (1/CysC)] - 4.32 
Bland and Altman analysis showed that the derived formula gave more accurate 
(P<0.0001) and more precise (P=0.024) GFR estimates than obtained with the Cockcroft- 
Gault formula. 
 
4) Filler GFR123:  
This Formula was developed from 536 children at Ottawa & Berlin (age ranging from 3 
months-18 years) comparing CysC measured by Dako PETIA method, to reference GFR 
measured by 51Cr EDTA clearance.,   
log(Filler GFR)=1.962 + [1.123  X  log(1/CysC)]. 
The formula which measured GFR in ml/min/1.73sq.m, had better correlation with 
EDTA clearance than the Schwartz formula (r=0.77 vs. 0.71 respectively).  
 
5) Macissac 124 GFR:  
This formula was derived from 251 patients in a Diabetic Clinic in Australia, the iGFR 
was measured by clearance of 99mTc-DTPA Clearance (78% having GFR > 
60ml/min/1.73sq.m.). The equation is as follows:  
Macissac GFR (ml/min/1.73sq.m) = (84.6/ CysC) - 3.2 
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6) Grubb GFR125:  
This is by far the most popular of the CysC based eGFR formulae. In this study, data 
from 536 patients (0.3–93 years), consecutively referred for determination of GFR by 
plasma Iohexol Clearance, were used for the analysis. CysC was measured using the 
Dako Cytomation PETIA method. A prediction equation using only CysC (in mg/L) and 
a prepubertal factor (Pf) assessed GFR (in ml/min/1.73sq.m) equally well or better than 
the MDRD-2, the Schwartz, and the Counahan–Barratt prediction equations for the 
juvenile and adult (>18 years) groups. Age did not influence the CysC (Dako) based 
prediction equation for adults, whereas gender did, but with a factor close to unity (0.948 
for females). The equations are: 
(1) Grubb age adjusted GFR = 84.69 X (CysC-1.680) X Pf         
 Pf = 1.384 if age < 14yrs;  Pf = 1.0 if age ≥ 14yrs. 
(2) Grubb age, sex adj. GFR = 87.62 X (CysC-1.693) X Pf X S 
 Pf = 1.376 if age < 14yrs;  Pf = 1.0 if age ≥ 14yrs; 
 S = 0.948 if female; S = 1 if male; 
 
7) Mayo Clinic CysC GFR126:  
In this study by Rule et.al, CysC (Dade Behring PENIA) and S.Cr levels were obtained 
from adult patients (n = 460) during an evaluation that included a GFR measurement by 
Iothalamate clearance (non-radiolabelled Iothalamate measured by capillary 
electrophoresis). It was notable that, at the same CysC level, GFR was 19% higher in 
transplant recipients than in patients with native kidney disease. The association between 
CysC and GFR was stronger among native kidney disease patients than in healthy 
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persons. As the relationship between CysC and GFR differed across clinical 
presentations, the GFR equation was modeled using the following variables: CysC (or 
S.Cr), age, gender, and clinical presentation (CKD patient vs. allograft recipient).  The 
equations are as follows: 
(1) Mayo CysC GFR (Tx) = 76.6 X (CysC)-1.16 
(2) Mayo CysC GFR (CKD)  = 66.8 X (CysC)-1.3 
(3) Mayo S.Cr GFR (CKD) = 273 x (S.Cr)-1.22 X age-0.299 X 0.738 if female 
(4) Mayo Composite GFR(CKD) = (CysC GFR X S.Cr GFR)0.5 
Among transplant recipients, the CysC equation (eqn. (1)) had an r2of 0.768. In CKD 
patients, the correlation of the CysC equation (eqn. (2), r2=0.853) was higher than the 
S.Cr equation derived using the same sample (eqn. (3), r2=0.827), the MDRD2 equation 
(r2=0.825) and the Cockcroft–Gault equation (r2=0.796).  
 
8) Dade Behring GFR:  
Coresh et.al, derived an equation using data from 1,935 adults in the CKD-EPI 
collaboration consisting of predominantly non-elderly CKD population. The Cystatin C 
was measured by Dade Behring PENIA method. The GFR equation is as follows: 
Dade Behring CysC GFR = 76.7 X (CysC) -1.18 
 
9) Zuo Combined GFR127:  
The Chinese eGFR Investigation Collaboration’s study is provides one of the few GFR 
equations modeled among Asian populations. The GFR equations were based on CysC 
(Dade Behring PENIA), S.Cr (Jaffe Kinetic method) and reference GFR measured by 
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99mTc-DTPA plasma clearance method in a training cohort of 376 randomly selected 
adult Chinese patients with CKD. Two individual equations, a composite equation of the 
two and a combined S.Cr - CysC equation that estimate GFR (in ml/min/1.73sq.m) were 
modeled on this population. They were validated by testing on an additional 191 patients.  
A final equation was then derived for best fit for all the 567 patients together.  The 
equations are as follows: 
(1) Zuo CysC GFR  
GFR1= 86 X (CysC)-1.132 
(2) Zuo S.Cr-CysC GFR 
GFR2 = 176  X  S.Cr-0.607  X  CysC-0.638  X  Age-0.171     X 0.85 for female 
(3) Modified MDRD2 for Chinese GFR 
GFR3= 175 X S.Cr-1.234 X Age-0.179 X 0.79 for female 
(4) Zuo Composite CysC-S.Cr GFR 
GFR4 = [(GFR1)  X  (GFR3)] 0.5 
(5) Zuo Combined GFR (final)  
GFR5 = 169 X S.Cr-0.608 X CysC-0.63 X Age-0.179 X 0.83 for female 
The Zuo Combined GFR equation (eqn.5) yielded considerable performance 
improvement compared with those of S.Cr (eqn.3) or CysC (eqn.1) based equations, and 
slight superiority to the composite equation (eqn.4) in each stage of CKD, particularly in 
patients with near-normal kidney function. It gave the best model fit; the R2 was higher 
than the individual equations (eqn. 1 & 3), and it also showed the smallest standard error 
of residual, the smallest relative and absolute difference, and the highest accuracy.  
 
 52
There were several potential limitations to all these studies.  
First, patients could have been misclassified into clinical presentations.  
Second, among native kidney disease patients, only those with an increased 
severity of illness, such that a nephrologist would measure the patient’s GFR, may have 
been represented. Thus, patients with microalbuminuria and a normal serum creatinine 
level could have been inadequately represented.  
Third, the generalizability of the CysC equations needs to be tested in other 
centers with more diverse racial groups and different mixtures of CKD etiologies.  
Finally, any calibration differences between the various methods used for assay of 
CysC used in these studies and other CysC assays can lead to inaccurate GFR estimates. 
 
In summary, it appears that in certain populations, CysC may be more accurate for 
assessment of kidney function than S.Cr. Whether measurement of CysC levels will 
improve patient care is at present unknown. 
 
4.0 STATISTICAL METHODS FOR GFR FORMULAE 
COMPARISON 
Review of the literature showed great heterogeneity in how the performance of prediction 
equations was assessed. Improper techniques and inadequate analyses have marred the 
clinical value of most of the studies in GFR estimation. Hence it is important to review 
the basic statistical analyses required while studying GFR prediction equations and 
understand the shortcomings of the same.  
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4.1 Bias, Precision and Accuracy  
In choosing a prediction equation to estimate GFR, one should consider both the bias and 
precision of the equation-generated estimates. Bias expresses the systematic deviation 
from the gold standard measure of GFR. A prediction equation that consistently 
overestimates or underestimates the gold standard measure of GFR yields a biased 
estimate. The mean difference between the actual measured GFR (gold standard) and the 
estimated GFR based on an equation is a valid measure of bias. The median difference 
provides a measure that is valid and less susceptible to influence by outliers. Precision 
expresses the variability (or dispersion) of prediction equation estimates around the gold 
standard GFR measure. The standard deviation of the difference between the measured 
and estimated GFR is a measure of precision. The difference from the gold standard can 
also be expressed as a relative difference, i.e., percent difference from the measured 
GFR. This has the advantage of allowing for the decreased absolute precision in 
estimating higher values of GFR. Clinically this is relevant, as there is less concern about 
the difference between 100 and 130 mL/min/1.73 Sq.m than between 30 and 60 
mL/min/1.73 Sq.m. Accuracy combines precision and bias. A useful measure of 
accuracy is a description of percentiles of the distribution of the differences between 
estimated and measured GFR. In other words, if 99% of the time a prediction equation 
yields an estimate within 10% of the measured GFR, it would be a very accurate and 
useful clinical tool. Achieving a high level of accuracy requires both low bias and high 
precision. Description of the percent of estimates falling within 30% and 50% above or 
below the measured GFR is a useful measure of accuracy.  
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4.2 Analysis and Interpretation of Data  
Correlation coefficients are frequently cited in the literature on prediction equations. 
However, they are inadequate for measuring the validity of a method in estimating GFR 
for two reasons.  
Although correlation coefficients (r) measure the association between prediction equation 
and measured GFR, the correlation coefficient is highly dependent on the distribution of 
GFRs in the study population selected. Even poor estimates can discriminate between a 
GFR of 20 and 120 very reliably.  
Second, correlation measures ignore bias and measure relative rather than absolute 
agreement. For example, in the MDRD Study the Cockcroft-Gault equation had a similar 
correlation to GFR as the MDRD Study equation but overestimated GFR by 19%4. 
Analogous studies in children show similar limitations in assessing the utility of a 
prediction equation by virtue of its correlation coefficient 6. The correlation between 
inulin clearance and estimated GFR by the Schwartz formula was 0.905, while in the 
same study, the standard deviation of the difference between the reference value (Cin) on 
the predicted value was 28.6%, indicating limited precision.  
Regression equations are another commonly used measure of prediction equations. 
Regression equations relating an estimate of GFR and the measured GFR provide an 
estimate of systematic bias, in the relationship between the two variables, as well as the 
correlation and residual root mean error, measures of precision. However, such regression 
analyses have two drawbacks.  
First, ordinary least square regression does not allow for measurement error in the X-
variable. As a result, the regression equation provides a prediction equation conditional of 
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the X-value rather than an unbiased estimate of the relationship. For example, a 
regression of one GFR measure on a second GFR measure, using the same technique on 
another day, would have a slope that is substantially lower than 1.0 and an intercept 
greater than zero. The importance of measurement error in the X-values depends on the 
correlation, which in turn depends on the study population.  
Second, regression equations cannot be pooled across different studies.  
Finally, evaluation of the accuracy of any equation for estimating GFR must be made in 
an independent group from the group in which the equation itself was derived.  
 
5.0 GFR ESTIMATION IN INDIA 
Until now, a normal reference range for GFR in healthy adult Indians (usually 
evaluated in potential kidney donors) has not been determined and values 
from western population are being used as reference. Barai S et al128 , on 
studying 610 Indian patients’ (250 males, 360 females, average age 35.16 
years) GFR by 99mTc-DTPA plasma clearance by Russell’s two sample method, 
observed a mean GFR  of 82.3 ± 21.3 and 80.8 ± 18.1 ml/min/1.73Sq.m in 
adult males and females were respectively. Similar reports have been 
documented other studies129. Such a low average GFR in healthy Indian 
adults is a subject of debate .We need better methods to confirm the 
reference GFR for our population. In spite of the various shortcomings,  DTPA 
clearance or scintigraphy and the estimation equations (unadjusted for 
Indian subjects) have been utilized in these studies. In India, monetary 
limitations and lack of standardization of assays precludes  accurate 
 56
assessment of GFR. For us, the question of a standard test for GFR 
measurement remains unanswered. 
Studies have been performed to look at the applicability of estimations using 
creatinine based equations. Mahajan et al130  studied the performance 
characteristics of the Cockcroft Gault formula, MDRD1, MDRD2, and the 24 
hour urine creatinine clearance among 173 voluntary kidney donors (mean 
age 44.1 yrs, M:F = 1:3) comparing with GFR assessment by 99mTcDTPA 
clearance. However, there was very poor correlation of all the formulae with 
the DTPA clearance, implying that these equations are suboptimal for donor 
evaluation. Cystatin C has not been well studied in the Indian population. 
John GT et al131, concluded that because of its large intraindividual 
variations, serial serum CysC estimation was very poor in detecting reduced 
renal function. There are no published studies in Indexed journals that looked 
at the applicability of the various eGFR prediction formulae and the CysC in 
the Indian renal allograft recipient population.  
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AIM 
To study the agreement between GFR estimated by various prediction formulae based on 
Serum Creatinine and Cystatin C with the GFR measured by 99mTc DTPA renal 
scintigraphy among renal allograft recipients. 
To determine which estimated GFR prediction formula predicts GFR measured by 99mTc 
DTPA renal scintigraphy with precision and accuracy in renal allograft recipients. 
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PATIENTS AND METHODS 
DESIGN AND LOCATION: This prospective study was conducted at the Department 
of Nephrology, Christian Medical College, Vellore.  
 
PATIENTS: Renal allograft recipients who satisfied the following Inclusion and 
exclusion criteria were included: 
INCLUSION CRITERIA:  Renal allograft recipients  
Renal transplantation done at Christian Medical College, 
Vellore 
Completed six months of intensive follow up 
Stable graft function 
On Prednisolone dose of 7.5 – 12.5 mg/day 
EXCLUSION CRITERIA:  Incomplete follow up 
    Unstable graft functions or Graft failure 
 
DURATION: Patients who underwent renal transplantation from January 2006 to June 
2007 were included and followed up to January 2008. 
 
METHODOLOGY: Renal allograft recipients who underwent renal transplantation at 
CMC, Vellore, were followed up for first six months intensively. As per existing 
protocols, at completion of the 6 months of intensive follow-up, patients underwent 
99mTc-DTPA scintigraphy to assess graft function. Anthropometric measurements of 
height and weight were measured. Biochemical analysis such as serum creatinine, serum 
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urea, serum albumin and serum Cystatin C were performed at this point. GFR estimated 
from various prediction equations based on serum creatinine and Cystatin C were 
compared with the GFR obtained from DTPA clearance study.  
 
MEASUREMENTS:  
1) Anthropometry: Height and Weight were measured on height and weighing scales, 
standardized according to the rules of Department of Legal Metrology of the Government 
of India. Anthropometric calculations were based on the following formulae: 
BSA  = Body surface area in Sq.m. (Du Bois 9 formula)  
= 0.20247 X (Height in cms/100)0.725 X (Weight in Kg)0.425 
LBW  = Lean Body Weight132 in Kg 
 = [(1.10- (0.03  X sex)] X (weight)) – {[128 + (sex X 20)] X   [(weight/height)2]} 
IBW  = Ideal Body Weight133, 134 
= 50 + {2.3 X [(height - 152.4) / 2.54]} for males 
= 49 + {1.7 X [(height - 152.4) / 2.54]} for females 
2) Clinical Biochemistry: 
Serum Creatinine: Serum creatinine was measured (in mg/dl) by the Modified Jaffe’s 
Kinetic Alkaline Picrate method (colorimetry) without deproteinization using Automated 
Chemistry Analyzer Olympus AU 2700 (Japan).  
Principle: Creatinine + Picric acid -------------> Creatinine picramate 
Explanation: Creatinine in the serum forms a coloured complex with picrate in alkaline 
solution. The rate of absorbance change of the coloured complex is proportional to the 
creatinine concentration. 
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Serum Urea: Serum urea is measured (in mg/dl) by Berthelot’s Method (enzymatic 
colorimetric) using the Automated Chemistry Analyzer Olympus AU 2700 (Japan). 
Principle: The Berthelot reaction, is a 
reaction where ammonia reacts with 
hypochlorite, phenol, a catalyst, and 
alkali to produce a stable blue complex 
(indophenol).  
Explanation: Urea measurement in 
our lab is based upon a modified 
Berthelot reaction wherein urease 
hydrolyzes urea to ammonia and 
carbamic acid. Carbamic acid 
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spontaneously decomposes into 
ammonia and carbon dioxide. 
Ammonia reacts with salicylate, 
nitroferricyanide and an alkaline 
solution of hypochlorite to yield a 
blue-green chromophore which is 
measured photometrically and is 
proportional to the amount of urea in 
the sample. 
Serum Albumin: Serum Albumin was measured (in gm/dl) by colorimetric, end point 
bromocresol green (BCG) method using the Automated Chemistry Analyzer Olympus 
AU 2700 (Japan).  
Principle: BCG + Albumin---------------------------ÆComplex with color change 
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Explanation: BCG is a yellow indicator, which changes color from yellow to blue green 
when binding to albumin. Turbidity is avoided by addition of Brij- 35 
Serum Cystatin C: Serum Cystatin C was measured (in mg/L) by Particle 
Enhanced Nephelometric Immuno Assay (PENIA) by Dade Behring BN 100 
Nephelometer.  
Principle and Explanation: Polystyrene coated with specific antibodies to human 
Cystatin C aggregates when mixed with particles containing Cystatin C. These aggregates 
scatter a beam of light passing through the sample. The intensity of the scattered light is 
proportional to the concentration of the Cystatin C in the sample. The result is evaluated 
by comparison with a standard of known concentration. 
3) Nuclear Medicine: Measured GFR (mGFR) by 99mTc-DTPA Renal scintigraphy: 
99mTc DTPA scintigraphy performed on the patients after the administration of 130 MBq 
of the radioactive isotope and the scans were performed based at specified time intervals. 
The gamma camera based clearance methods are based on detection of the percent dose 
uptake of 99mTc-DTPA during the time interval in which none of the 99mTc-DTPA has 
entered the renal pelvis. Thus all filtered and secreted 99mTc-DTPA  is within the 
kidney. DTPA clearance is estimated using the Modified Gates31 method as follows: 
 
DTPA Clearance = [9.8127 X (Graft uptake %) – 6.82519] X 1.73 / BSA 
 
Uptake %   = 100 X Integral interval / (Injected dose X DCA)  
      [(Graft Counts – Background counts) / DCA] 
= ------------------------------------------------------------------- X 100 
         Pre syringe counts – post syringe counts 
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DCA  = exp (-0.153 X GD), 
GD  = graft depth in cm (Measured by an on-site CT scan / USG  
   From skin to the mid point of the mid polar renal tissue) 
Injected dose is determined by: 
o acquisition of a full and empty syringe,  
o entering the injected dose and time of measurement of injected dose. 
Integral Interval = 120 -180 seconds 
The DTPA Clearance is read as measured GFR (mGFR) adjusted to a BSA of 1.73Sq.m. 
4) Estimation of GFR (eGFR formulae):  
The following GFR formulae were used for estimation of GFR (pre corrected to report 
GFR in ml/min/1.73Sq.m.): 
1. eGFR based on serum creatinine: 
1.Cockcroft-Gault GFR  
CGGFR = {[(140-age) X weight] / (72 X S.Cr)} X (0.85 if female) X 1.73/BSA  
CGIWGFR = {[(140-age) X IBW] / (72 X S.Cr)} X (0.85 if female) X 1.73/BSA  
CGLWGFR = {[(140-age) X LBW] / (72 X S.Cr)} X (0.85 if female) X 1.73/BSA 
2. Six variable Original MDRD1 GFR  
MDRD-1 GFR = 170  X  (S.Cr) -0.999  X  age-0.176  X  (Ur X 2.78)-0.17  X  alb0.318  X  
(0.762 if female)  X  (1.18 if African-American) 
3.Four variable abbreviated MDRD2 GFR  
MDRD2 GFR  =  186  X   (S.Cr)-1.154   X   (Age)-0.203    X    (0.742 if female)    
X  (1.210 if African American) 
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4.Nankivell GFR  
NKVLGFR = [6700 / (S.Cr X 88.4)] + (weight/4) - (urea/12) – [100/ (height) 2] + 35  
– [10 (if female)] 
5.Mayo clinic quadratic GFR  
MCQGFR = exp [1.911+ (5.249 / S.Cr) – (2.114 / S.Cr2) - (0.00686 X Age)  
– 0.205(if female)] 
2. eGFR based on serum Cystatin C: 
6.Le Bricon GFR: LEBGFR = 78 X (1/CysC) + 4 
7.Larsson GFR:  LSNGFR = 77.24 X (CysC)-1.2623 X 1.73/BSA 
8.Hoeck GFR: HKGFR = [80.35 X (1/CysC)] - 4.32 
9.Grubb age adjusted GFR: GAGFR = 84.69 X (CysC-1.680) X Pf   
Pf = 1.384 if age < 14yrs; Pf = 1.0 if age ≥ 14yrs. 
10. Grubb age & sex adjusted GFR: GASGFR = 87.62 X (CysC-1.693) X Pf X S  
Pf = 1.376 if age < 14yrs; Pf = 1.0 if age ≥ 14yrs; S = 0.948 if female; S = 1 if male;  
11. Macissac GFR:  MACGFR = (84.6/ CysC) - 3.2  
12. Mayo Clinic CysC Tx GFR: MCTXGFR = 76.6 X (CysC)-1.16 
13. Zuo Combined GFR:  
ZCOMGFR = 169 X S.Cr-0.608 X CysC-0.63 X Age-0.179 X 0.83 for female 
The eGFRs were pre-adjusted to a BSA of 1.73 Sq.m for comparability.  
SAMPLE SIZE: 
Parameter Value 
Sample reliability value 0.52 
Population reliability value 0.95 
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Study sample size 134 
Alpha error 5 
Power obtained 99.9% 
 
STATISTICAL ANALYSIS:  
Statistical analysis was performed using the SPSS version 11.5 and Microsoft Excel 
2003. The various analytical techniques used for comparison of the estimated and 
measured GFR are as follows: 
1. Measures of central tendency and distribution – Mean ± standard deviations 
were used for normally distributed data and median & range (min – max) was 
used for skewed data to avoid the outlier effect.  
2. An intra-class correlation coefficient (one way random) was calculated for the 
eGFR and the mGFR and their significance was determined. Scatter plots were 
used for graphical representation of the same.  
3. Bias and precision were calculated based on the following definitions and 
graphically demonstrated using Bland -Altman analysis plots 
a. Bias  = Mean difference (eGFR – mGFR) 
b. Precision – 2 Std. deviation of Bias = 2  X  S.D (eGFR – mGFR) 
4. Relative Bias and Accuracy of eGFRs to predict mGFR were calculated: 
a. Relative Bias - % of difference between eGFR & mGFR (as % of  mGFR) 
Relative Bias (RB) = (Bias / mGFR) X 100 
b. Accuracy – % of eGFR values falling within a set RB : Accuracy @ 
i. 30% = [(no. of eGFR values with RB ≤ 30%) / (total =134)] X 100 
 66
ii. 50% = [(no. of eGFR values with RB ≤ 50%) / (total =134)] X 100 
5. Kappa statistics for agreement for GFR based classification (into three groups, 
GFR<30, 30-60 and >60 ml/min/1.73Sq.m) by the various eGFR equations and 
the mGFR were studied. The agreement was ascertained by the following scale: 
<0.20 - Poor; 0.21-0.40 - Fair; 0.41-0.60 - Moderate; 0.61-0.80 - Good; 0.81-0.99 
-Very good; 1.00 – Perfect agreement. The percentage of total number of patients 
misclassified into different group by the eGFR equation in study was also derived 
from the cross-tabulations. 
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RESULTS 
Patient Profile: During the enrollment period between January 2006 to June 2007, 143 
patients underwent renal transplantation at Christian Medical College, Vellore. Of them, 
134 patients were eligible and were included into the study: 
Figure 7.Case profile of the study 
 
Clinical Details: The study comprised predominantly of adults. Seven patients had age 
between 15 and 18 years. Majority of them received their grafts from live related donors 
Table 7. Demographic profile 
Total Number of patients 134 
Males : Females 101:33  (3:1) 
Age (in years) mean ± S.D 
Age Median (min-max) 
  34.0 ± 11.5  
33.0 (15.0 – 61.0) 
Live – related renal transplantation 128   (95.5%) 
Deceased Donor renal transplantation     6     (4.5%) 
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Nearly half the patients received the standard Prednisolone, Tacrolimus and 
Mycophenolate based triple immunosuppression. Another 40% received Cyclosporine. 
Table 8. Immunosuppression 
Immunosuppression Number  Percentage (n=134) 
Pred + CsA + Aza 31 23.1 
Pred + CsA + MPA 25 18.7 
Pred + Tac + Aza 10 7.5 
Pred + Tac + MPA 65 48.5 
Pred + Siro/Eve + MPA / Aza 3 2.2 
 
Anthropometry: The Anthropometric details were as follows. The average height and 
weight were 164 cm and 60Kg. However, there were some outliers. The mean BSA in 
our population was 0.07Sq.m less than the standard 1.73Sq.m in the west. 
Table 9. Anthropometric profile 
Measure mean ± S.D Median (min- max) 
Height in cm 163.7 ± 8.6 165.0    (148.0 - 185.0) 
Weight in Kg 59.7 ± 9.9 60.0      (42.0 – 124.0) 
Body surface area in Sq.m. 1.64 ± 0.15 1.66      (1.33 – 2.39) 
Lean Body weight in Kg 47.3 ± 6.7 47.1      (33.3 – 74.3) 
Ideal Body weight in Kg 59.8 ± 8.1 61.4      (46.0 – 79.5) 
 
Clinical Chemistry: The median serum Creatinine was 1.2 mg/dl, reflecting general 
well being of the graft at the end of six months follow up. This was substantiated by the 
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fact that majority of the patients have a 24 hour urine protein less than 1 gm/day. The 
serum Biochemical profile of our patients in given in Table 10.    
Table 10. Biochemical profile 
Measure mean ± S.D Median (min- max) 
Serum Creatinine in mg/dl   1.3 ± 0.4 1.2 (0.7 – 3.2) 
Serum Urea in mg/dl 33.8 ± 14.2 31.0 (15.0 – 110.0) 
Serum Albumin in gm/dl   4.2 ± 0.4 4.3 (2.6 – 5.1) 
Serum Cystatin C in mg/L   1.67 ± 0.63 1.50 (0.89 – 5.55) 
24 hour urine protein in mg/day 245.8 ± 377.7 150.0 (48.0 – 3100.0) 
 
Measured and Estimated GFR: The median, 5th and 95th percentiles of  mGFR from 
DTPA renal scintigraphy were 49, 19.9 and 97 ml/min/1.73Sq.m  respectively.  The 
distribution of the various eGFRs are depicting in Table 11 and Figure 8. The eGFR 
ranges for the S.Cr. based equations is much higher compared to the mGFR. However, 
the Cockcroft-Gault equation using lean body weight instead of actual body weight has a 
distribution closer to the mGFR range.  Cystatin C based equations predicted eGFR 
ranges are similar (if not lower) compared to the mGFR distribution. The equation with 
the a median eGFR similar to the mGFR range would be the Larsson and the Macissac 
CysC based equation.  
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Table 11. The mGFR and eGFR distribution 
Measure (in ml/min/1.73Sq.m.) mean ± S.D Median (min- max) 
99mTc-DTPA Clearance (mGFR)  52.1 ± 22.6 49.0 (11.0 – 113.0) 
eGFR based on S.Creatinine:   
CGGFR 70.7 ± 16.5 70.5 (26.7 – 145.0) 
CGIWGFR 71.2 ± 16.9 70.9 (25.5 – 109.7) 
CGLWGFR 56.1 ± 12.3 56.8 (21.2 – 86.8) 
MDRD1GFR 65.4 ± 17.5 66.5 (19.8 – 122.8) 
MDRD2GFR 71.3 ± 18.3 70.9 (21.9 – 127.3) 
NKVLGFR 71.8 ± 14.0 72.2 (35.3 – 107.2) 
MCQGFR 92.2 ± 25.6 94.5 (20.0 – 150.1) 
Measure (in ml/min/1.73Sq.m.) mean ± S.D Median (min- max) 
eGFR based on S. Cystatin C:   
LEBGFR 55.4 ± 14.4 56.0 (18.1 – 91.6) 
LSNGFR 49.6 ± 19.4 49.3 (8.5 – 109.5) 
GAGFR 43.9 ± 19.9 42.9 (4.8 – 103.0) 
GASGFR 44.4 ± 19.9 43.5 (4.8 – 100.9) 
HKGFR 48.6 ± 14.9 49.2 (10.2 – 86.0) 
MCTXGFR 47.6 ± 15.3 47.9 (10.5 – 87.7) 
MACGFR 52.5 ± 15.7 53.2 (12.1 – 91.9)  
ZCOMGFR 65.4 ± 18.8 65.1 (15.3 – 110.2) 
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Figure 8. Distribution of the mGFR and various eGFR values. Dotted lines represent the median, 5th and the 95th percentile of 
mGFR values 
GFR methods
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Comparison between the mGFR and eGFR: 
1. Intra Class Correlation Coefficients: The various intra-class correlation coefficients 
for the various eGFR equations are listed in Table 12. Most of the S.Cr based equations 
have poor or no correlation with mGFR. The commonly used Cockcroft Gault GFR and 
the Nankivell GFR (that was developed exclusively from renal transplant recipients) 
fared the worst with ICC of 0.03 and 0.05 respectively. However, among them the 
formulae with higher degree of correlation are the original six variable MDRD equation 
(MDRD1 with ICC=0.36), closely followed by the Abbreviated four variable MDRD 
equation (MDRD2 with ICC = 0.26) and the Cockcroft-Gault GFR using lean body 
weight (CGLW with ICC = 0.25). In contrast, the CysC based equations fared better. The 
best correlating eGFR equations were the Larsson eGFR and the Macissac eGFR (ICCs 
of 0.57 and 0.50 respectively). The widely used Grubb CysC equations had an ICC of 
0.46. Mayo Clinic CysC GFR and Le Bricon GFR (both derived from renal transplant 
recipients) had ICC of 0.47 each. None of the equations attained an ICC > 0.60.  
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Table 12. Intra Class Correlation between various eGFRs and the mGFR 
95% C.I. Variable ICC 
Lower bound Upper bound 
p value 
CGGFR 0.03 -0.14 0.19 0.371 
CGIWGFR 0.12 -0.05 0.28 0.088 
CGLWGFR 0.25 0.08 0.40 0.002 
MDRD1GFR 0.36 0.20 0.49 <0.001 
MDRD2GFR 0.26 0.09 0.41 0.001 
NKVLGFR 0.05 -0.12 0.22 0.269 
MCQGFR -0.06 -0.23 0.11 0.756 
LEBGFR 0.47 0.33 0.60 <0.001 
LSNGFR 0.57 0.45 0.68 <0.001 
GAGFR 0.46 0.32 0.58 <0.001 
GASGFR 0.46  0.32 0.58 <0.001 
HKGFR 0.48 0.34 0.60 <0.001 
MCTXGFR 0.47 0.33 0.60 <0.001 
MACGFR 0.50 0.36 0.62 <0.001 
ZCOMGFR 0.42 0.27 0.55 <0.001 
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Figure 9: Scatter plots for eGFRs vs. mGFR 
 
 
 
 
 
                                                                                                                                      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. Bland Altman Analysis: Bias, Precision, Relative Bias and Accuracy: 
(a) (b) 
(c) (d) 
(e) (f) 
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2) Bland-Altman Analysis of Bias and Precision:  
The S.Cr based eGFR equations seem to overestimate the GFR by an average of 15-
20ml/min/1.73Sq.m. Least bias was observed for the Cockcroft-Gault formula using the 
lean body mass for calculation (CGLW with Bias of +4.0 ± 22.2ml/min/1.73sq.m.). 
However, the CysC based equations had comparatively much less bias (1-10 
ml/min/1.73Sq.m) Least bias was observed for the Larsson GFR (-2.4 ± 19.5 
ml/min/1.73Sq.m) and Macissac GFR(0.5 ± 19.5 ml/min/1.73Sq.m) . Precision (2 SD of 
the Bias) was equally poor for all the eGFR equations (approx. ±40ml/min/1.73sq.m.). 
The precision was marginally better for the CysC based equations (±35-
40ml/min/1.73Sq.m) compared to the S.Cr based equations (±40-50ml/min/1.73Sq.m). 
 
3) Relative Bias and Accuracy:    
Relative Bias was much higher for the S.Cr based equations (40-50%) compared to the 
CysC based equations (24-28%). Accuracy at 30%  and 50% was poor for all S.Cr based 
equations (30-40% and 50-60% respectively). Among the S.Cr based eGFRs, Cockcroft-
Gault GFR using lean body weight had the least ‘relative’ bias (32.1%) and best accuracy 
(@30% - 47.8%, @50% - 72.1%). Overall least relative bias and best accuracy was 
observed for the Larsson , Macissac and the Mayo Clinic CysC GFRs.  
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Table 13. Bias and Precision of eGFR to mGFR 
95% C.I. of bias 
ml/min/1.73m2 
eGFR Bias 
(mean±SD) 
ml/min/1.73m2 Lower 
bound 
Upper bound
Precision       
± 2SD 
ml/min/1.73m2 
p 
Value 
CGGFR 18.7± 24.2 14.5 22.8 48.3 <0.001
CGIWGFR 19.2 ± 22.4 15.3 23.0 44.7 <0.001
CGLWGFR 4.0 ± 22.2 0.2 7.8 44.3 0.039 
MDRD1GFR 13.4 ± 20.2 9.9 16.8 40.4 <0.001
MDRD2GFR 19.2 ± 20.0 15.8 22.6 40.0 <0.001
NKVLGFR 19.7 ± 21.6 16.0 23.4 43.2 <0.001
MCQGFR 40.1 ± 21.9 36.3 43.8 43.9 <0.001
LEBGFR 3.3 ± 19.3 0.0 6.6 38.6 0.049 
LSNGFR -2.4 ± 19.5 -5.8 0.9 38.9 0.149 
GAGFR -8.2 ± 21.0 -11.8 -4.6 42.1 <0.001
GASGFR -7.7 ± 21.7 -11.3 -4.1 42.3 <0.001
HKGFR -3.5 ± 19.8 -6.8 -0.2 38.7 0.040 
MCTXGFR -4.5 ± 19.5 -7.8 -1.2 38.9 0.008 
MACGFR 0.5 ± 19.5 -2.9 3.8 39.0 0.784 
ZCOMGFR 13.4 ± 19.3 10.1 16.7 38.6 <0.001
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Figure 10.Bland Altman Plots for eGFR – mGFR pairs 
(CGGFR+ mGFR)/2
120.00100.0080.0060.0040.0020.00
C
G
G
FR
 - 
m
G
FR
150.00
100.00
50.00
0.00
-50.00
18.7
66.9
-29.7
(a) Cockcroft Gault GFR with mGFR
(CGLWGFR + mGFR)/2
100.0080.0060.0040.0020.000.00
C
G
LW
G
FR
 - 
m
G
FR
50.00
25.00
0.00
-25.00
-50.00
-75.00
4.0
48.3
-40.3
(b) Cockcroft Gault GFR with LBW and mGFR
(MDRD1 + mGFR)/2
120.00100.0080.0060.0040.0020.000.00
M
D
R
D
1 
- m
G
FR
50.00
25.00
0.00
-25.00
-50.00
-75.00
13.4
53.7
-27.0
(c) MDRD1 GFR with mGFR
(MDRD2 + mGFR)/2
120.00100.0080.0060.0040.0020.000.00
M
D
R
D
2 
- m
G
FR
50.00
25.00
0.00
-25.00
-50.00
19.2
59.2
-20.8
(d) MDRD2 GFR with mGFR
(LEBGFR + mGFR)/2
100.0080.0060.0040.0020.000.00
LE
B
G
FR
 - 
m
G
FR
40.00
20.00
0.00
-20.00
-40.00
-60.00
-80.00
3.3
41.9
-35.25
(e) Le Bricon CysC GFR with mGFR
(LSNGFR + mGFR)/2
100.0080.0060.0040.0020.000.00
LS
N
G
FR
 - 
m
G
FR
50.00
25.00
0.00
-25.00
-50.00
-75.00
-2.4
36.4
-41.3
(f) Larsson CysC GFR with mGFR
 
(GASGFR + mGFR)/2
100.0080.0060.0040.0020.000.00
G
A
SG
FR
 - 
m
G
FR
50.00
25.00
0.00
-25.00
-50.00
-75.00
-7.7
34.5
-50.0
(g) Grubb Age and Sex Adjusted CysC GFR with mGFR
(MACGFR + mGFR)/2
100.0080.0060.0040.0020.000.00
M
A
C
G
FR
 - 
m
G
FR
40.00
20.00
0.00
-20.00
-40.00
-60.00
-80.00
0.5
39.4
-38.5
(h) Macissac CysC GFR with mGFR
 
 
 
 78
Table 14. Relative Bias and accuracy of eGFR to mGFR 
Accuracy at (%) eGFR Equation 
Tested 
Median Relative 
Bias (RB) (%) 30% RB 50% RB 
CGGFR 45.9 35.8 52.2 
CGIWGFR 51.1 31.3 50.0 
CGLWGFR 32.1 47.8 72.1 
MDRD1GFR 41.3 38.1 59.7 
MDRD2GFR 52.1 32.1 48.5 
NKVLGFR 48.2 33.6 50.7 
MCQGFR 81.0 12.7 29.1 
LEBGFR 26.7 55.2 76.9 
LSNGFR 23.7 61.2 87.3 
GAGFR 28.1 61.2 81.3 
GASGFR 26.7 62.7 80.6 
HKGFR 24.8 58.2 85.8 
MCTXGFR 24.8 61.9 85.8 
MACGFR 24.6 59.7 83.6 
ZCOMGFR 37.7 40.3 62.7 
 
3) Agreement statistics on GFR classification: GFR was classified into three groups - 
<30, 30-60 and >60 ml/min/1.73m2 based on mGFR and the various eGFR. The Kappa 
statistics of agreement between the eGFR and the mGFR classes were studied. The S.Cr 
based equations misclassified nearly 50-60% of the patients to a different GFR group. 
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They consequently had the worst agreement uniformly (K= 0.05-0.20). CysC based 
equations fared slightly better with % misclassified being 30-40% (K = 0.30-0.45). The 
equations that best agreed with mGFR were Larsson and the Mayo Clinic CysC GFR. 
Table 15. Kappa statistics for GFR classification based on mGFR and various eGFRs 
GFR class (no. of patients) GFR 
≥60 30-60 <30 
%misclassified
n=134 
Kappa 
statistics 
Agreement p value 
DTPAGFR 44 69 21 - - - - 
CGGFR 102 31 1 56.7 0.10 Poor 0.058 
CGIWGFR 99 34 1 59.0 0.06 Poor 0.290 
CGLWGFR 54 78 2 50.8 0.10 Poor 0.130 
MDRD1GFR 79 52 3 49.3 0.18 Poor 0.004 
MDRD2GFR 98 35 1 53.8 0.14 Poor 0.011 
NKVLGFR 107 27 0 59.7 0.07 Poor 0.128 
MCQGFR 116 17 1 62.0 0.05 Poor 0.255 
LEBGFR 51 79 4 41.8 0.26 Fair <0.001 
LSNGFR 36 78 20 34.2 0.42 Moderate <0.001 
GAGFR 26 69 39 40.3 0.36 Fair <0.001 
GASGFR 28 69 37 39.5 0.37 Fair <0.001 
HKGFR 30 91 13 33.6 0.40 Fair <0.001 
MCTXGFR 29 87 18 31.3 0.45 Moderate <0.001 
MACGFR 44 81 9 40.2 0.29 Fair <0.001 
ZCOMGFR 76 55 3 46.3 0.23 Fair <0.001 
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DISCUSSION 
Estimation of the glomerular filtration rate in is an important part of management of renal 
transplant recipients. As direct measurements of GFR are cumbersome, several prediction 
equations have been derived on various population subsets to predict the GFR based  on 
endogenous serum markers. Nephrologists rely on direct methods only when the clinical 
picture does not correlate with the eGFR. Several studies have evaluated the utility of the 
eGFR equations in the renal allograft recipients in the west, though none have been tested 
or validated among the Brown Caucasian allograft recipients of the Indian subcontinent. 
Our study was designed to assess the performance characteristics of the various S.Cr and 
CysC based eGFR equations in predicting the measured GFR (by 99mTc DTPA 
renography) among renal allograft recipients of the Indian subcontinent.   
Our results show that the mGFR tends to differ significantly from the eGFR. The S.Cr 
based equations fared poorly in all respects of comparison with mGFR. Their eGFR 
ranges were much higher than the mGFR range. They had higher bias, poor precision, 
low accuracy and poor agreement with mGFR. Nearly 60% of patients are misclassified 
into different GFR groups using S.Cr eGFRs . The widely used Cockcroft Gault GFR had 
one of the worst performance characteristics. The abbreviated four variable MDRD2 
equation was not better than the other S.Cr eGFRs.  The Nankivell GFR was derived on a 
cohort of Australian renal allograft recipients to estimate GFR measured by DTPA 
clearance. In spite of the similarities in test situation to our study, it had poor correlation, 
high bias and low accuracy compared to other S.Cr eGFRs. Only the original six variable 
MDRD1 and the Cockcroft-Gault equation using lean body weight fared slightly better 
than the rest. Nevertheless, their performance characteristics were generally poor. 
 81
Comparatively, the CysC based equations have fared better. They had lesser bias, though 
precision was similar to the S.Cr based equations. They also had greater accuracy, and 
better agreement with mGFR. Among the various CysC based equations the Larsson 
GFR, the Macissac GFR and the Mayo Clinic CysC GFR estimates have the best 
performance characteristics. The Zuo combined GFR based on both S.Cr and CysC 
derived from Chinese population, performed worse than all CysC based equations, 
possibly due to S.Cr related factors.  
There are several important lessons from these results. S.Cr seems to be a poor indicator 
of renal function in renal allograft recipients. In most of the cases, S.Cr based eGFR 
overestimates renal function. The MDRD2 and Cockcroft Gault equations, recommended 
by NKF-KDOQI may not apply to renal allograft recipients of Indian subcontinent. As 
S.Cr is widely and frequently used for monitoring renal allograft recipients, it is 
important to bear in mind that early reductions in GFR may be underestimated by the 
S.Cr based eGFR equations. Care of the renal allograft recipient in the early post 
transplant period can be compromised by such an overestimated view of his/her GFR.  
There are many reasons for these observations. Tubular secretion is increased in renal 
allografts, resulting in lowering of S.Cr without an increment in GFR. The degree of 
tubular secretion is not uniform and seems independent of the GFR. In addition, 
hyperfiltration by renal allografts may also reduce S.Cr. The malnourished chronic 
kidney disease patient with poor muscle mass has significant weight gain in the first 6 
months after renal transplantation. However, most of the weight gain is due to body fat 
and not muscle mass. Hence, S.Cr levels may be low for the given body weight, resulting 
in overestimation of GFR. The fact that Cockcroft Gault GFR using Lean Body Weight 
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had better performance characteristics compared to all other S.Cr eGFRs supports the 
hypothesis. The S.Cr. in our study, measured by Jaffe reaction (alkaline picrate) using an 
auto-analyzer, has not been standardized to the IDMS traceable S.Cr values. This is 
especially of importance while using the abbreviated four variable MDRD2 equation. 
Even though we have used the equation meant for the non standardized creatinine, it has 
wide variation and hence resulted in poorer performance of the abbreviated four variable 
MDRD2 equation in our study. The S.Cr eGFR equations were derived based on different 
reference methods of GFR measurement. They may hence not perform adequately 
satisfactorily when compared with another method of GFR estimation.  In addition, 
DTPA clearance has not been validated against Inulin or Polyfructosan clearance in 
Indian population. The Gates method of DTPA scintigraphy based GFR estimation is 
considered inferior to the plasma sample clearance methods. The variation in the 
clearance measure due to technical differences adds to the accumulating errors in GFR 
estimation by prediction equations. This may be the reason for the relatively uniform 
poor precision among both the S.Cr and the CysC based equations. In addition, the 
validity of the Du Bois formula for assessment of body surface area in the Indian 
population has not been proven. Errors in this formula will add up to the variation in 
eGFR since all the GFR values were standardized to a BSA of 1.73Sq.m for 
comparability.  This may be another contributor to the large S.D of bias (Precision) 
observed in both the CysC and S.Cr based equations.  
CysC based formulae had minimal or negative bias, better accuracy and better agreement 
with the mGFR. The several advantages of CysC over S.Cr have already been listed in 
the review of literature section. CysC is not secreted in the renal tubules, thereby 
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minimizing errors due to secretion as observed with S.Cr. Nevertheless, Cystatin C levels 
may be elevated marginally with use of steroids in renal allograft recipients. To avoid this 
bias, we have selected patients on a stable and small dose of prednisolone (7.5 to 12.5 
mg/day), unlikely to affect the CysC value significantly. Cyclosporine may reduce CysC 
levels thereby resulting in underestimation of GFR. The effect of Tacrolimus on CysC 
levels is unknown. The Larsson GFR, the Macissac GFR and the Mayo Clinic CysC GFR 
had better performance characteristics compared to the widely accepted Grubb GFR and 
should be used to estimate GFR better in the transplant recipient. The overall poor 
performance of all the equations prompts for further research into GFR estimation in 
Indian population. The future lies in deriving a specific eGFR equation for Indian 
population based on a gold standard technique such as Inulin or Polyfructosan clearance.  
In view of these findings, several steps have been taken towards estimating GFR 
accurately in our setting. Firstly, CysC has been introduced as a clinical test for monthly 
evaluation of renal function in renal allograft recipients. Secondly, S.Cr measurement is 
being standardized to the IDMS traceable S.Cr as per MDRD study protocol. Thirdly, 
Plasma Clearance method of DTPA GFR estimation has been introduced and is currently 
being validated. We have also tried to acquire Polyfructosan Inutest® from Fresenius 
Kabi, Austria for studying GFR by gold standard method. A GFR calculator with the 
Larsson, Macissac and the Mayo Clinic CysC GFR equations along with the standard 
Creatinine based equations is being developed for ready interpretation of the CysC based 
GFRs in our Transplant Clinic.  
 
 
 84
SUMMARY 
We studied 134 renal allograft recipients (101 males, 33 females; average age 34.0 ± 
11.5years). GFR at 6 months post renal transplant was measured by 99mTc DTPA 
scintigraphy (mGFR). GFR was estimated (eGFR) by the various S.creatinine based 
equations (Cockcroft-Gault GFR, Cockcroft-Gault GFR with ideal body weight, 
Cockcroft-Gault GFR with lean body weight, MDRD1 GFR, Abbreviated MDRD2 GFR, 
Nankivell GFR and Mayo Clinic Quadratic GFR) and S.Cystatin C based eGFR 
equations (Le Bricon, Larsson, Grubb age adjusted, Grubb age and sex adjusted, Hoeck, 
Mayo Clinic CysC Transplant GFR, Macissac and Zuo Combined GFR). The mean 
mGFR was 52.1 ± 22.6 ml/min/1.73Sq.m. Overall, the measured GFR was different from 
estimated GFR. The S.Cr based equations overestimated GFR [high bias +15to20 
±25ml/min/1.73Sq.m.] and had poor correlation (0.0-0.4), poor accuracy (@30% - 35%; 
@50% - 55%) and poor agreement (K = 0.05-0.20; 50-60% misclassified) with mGFR.  
Among them, the MDRD1, MDRD2 & CG-LW GFRs had marginal correlation with 
mGFR (ICC= 0.25-0.35). CG-LW GFR had the least bias (+4.0 ± 22.4ml/min/1.73Sq.m; 
RB -32.1%) and most accuracy (@30% - 47.8%; @50% - 72.1%) among the S.Cr 
eGFRs.  When compared to the S.Cr eGFR, all CysC eGFRs had better correlation (ICC= 
0.45-0.50), lower bias (-10 to +1 ± 20ml/min/1.73Sq.m), higher accuracy (@30% - 60%; 
@50% - 80%) and better agreement (K = 0.25-0.45; 35-40% misclassified) with the 
mGFR. Among them the Larsson GFR, the Macissac GFR and the Mayo Clinic CysC TX 
GFR have the best performance characteristics in renal allograft recipients of Indian 
subcontinent. 
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CONLUSIONS 
In renal allograft recipients of the Indian subcontinent, 
1) The S.Cr based eGFR estimates poorly correlate, widely differ and rarely agree 
with the measured GFR (mGFR – by 99mTc-DTPA renal scintigraphy), whereas 
the CysC based eGFR estimates correlate well, differ slightly and moderately 
agree with mGFR. 
2) Among all eGFRs, the CysC based equations Larsson GFR, Macissac GFR and 
the Mayo Clinic CysC Tx GFR provide the best GFR estimates  
3) Among the S.Cr eGFRs, Cockcroft-Gault GFR using lean body weight provides 
the best GFR estimates 
4) CysC is a better predictor of GFR than S.Cr at 6 months post transplantation 
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PROFORMA 
1. Case No. 
2. Name: 
3. Hospital Number: 
4. Age in yrs: 
5. Sex: Male – 0 / Female - 1 
6. Date of Transplantation:  
7. Donor – Live related – 0 / Cadaver – 1 
8. Immunosuppression: 
1. Pred +CsA + Aza 
2. Pred + CsA + MPA 
3. Pred + Tac + Aza 
4. Pred + Tac + MPA 
5. Others : specify: 
AT 6 MONTHS: 
9. Height in cm: 
10. Weight in Kg: 
11. S. Creat in mg/dl: 
12. S.Urea in mg/dl: 
13. S.Albumin in gm/dl: 
14. S.Cystatin C in mg/L: 
15. 24 hour urine protein: 
99mTc – DTPA renography 
16. Renal scintigraphy performed – Yes / No 
17. Compound used – Tc DTPA / DMSA / EC 
18. Depth corrected? Yes / No 
19. DTPA clearance in ml/min/1.73m2:  
sno name hospnum age sex race dotx cada ims ht wt bsa lbw idbw
1 JAIRUL HAQUE 653728C 46 0 0 05-Jan-2006 0 1 168.0 57.0 1.64 47.97 64.1
2 KANU DEBNATH 678639C 24 0 0 12-Jan-2006 0 1 168.0 56.5 1.64 47.67 64.1
3 GAYATHRI 032034B 16 1 0 17-Jan-2006 1 5 154.0 53.0 1.50 39.18 50.1
4 RANGANATHAN 388879C 54 0 0 17-Jan-2006 1 1 173.0 60.5 1.72 50.90 68.7
5 KRISHNA GHOSH 684669C 33 1 0 04-Jan-2006 0 1 163.0 62.0 1.67 44.93 56.1
6 RICHARD LALNUNPUIA 745105C 29 0 0 10-Jan-2006 0 1 170.0 63.0 1.73 51.72 65.9
7 BALMAYA DAHAL 742626C 20 1 0 11-Jan-2006 0 1 150.0 52.5 1.46 38.05 47.4
8 MOHD MASUM 749468C 19 0 0 18-Jan-2006 0 1 156.0 56.0 1.55 45.11 53.3
9 RAM G GANGULI 911128B 41 0 0 08-Feb-2006 0 1 160.0 65.0 1.68 50.38 56.9
10 TSHERING TASHI 752859C 24 0 0 22-Feb-2006 0 1 162.0 47.0 1.48 40.93 58.7
11 BIJOY PRASAD 738274C 38 0 0 23-Feb-2006 0 1 166.0 61.0 1.68 49.82 62.3
12 PRAKASH BAIDYA 750298C 38 0 0 01-Mar-2006 0 1 176.0 65.0 1.80 54.04 71.4
13 SAIFUL ISLAM 726123C 30 0 0 02-Mar-2006 0 1 165.0 58.5 1.64 48.26 61.4
14 RANGARAJULU 512177C 47 0 0 07-Mar-2006 0 1 173.0 71.0 1.84 56.54 68.7
15 CHANDRASEKAR 734235C 34 0 0 08-Mar-2006 0 1 163.0 64.0 1.69 50.67 59.6
16 RATAN KANTI KHAR 740468C 50 0 0 15-Mar-2006 0 2 169.0 65.5 1.75 52.82 65.0
17 LALAN KUMAR 624491C 54 0 0 16-Mar-2006 0 1 158.0 58.0 1.58 46.55 55.1
18 GANESH KUMAR 761506C 27 0 0 21-Mar-2006 0 1 158.0 55.0 1.55 44.99 55.1
19 SITA DEVI 765975C 45 1 0 23-Mar-2006 0 1 150.0 61.0 1.56 40.79 47.4
20 FALAN MOLLA 778036C 40 0 0 28-Mar-2006 0 1 173.0 63.0 1.75 52.33 68.7
21 PAVANI LAKSHMII 334860C 22 1 0 29-Mar-2006 0 1 164.0 66.0 1.72 46.65 56.8
22 JAYANATH KR SINGHA 728810C 41 0 0 04-Apr-2006 0 1 172.0 69.0 1.81 55.30 67.7
23 HARUNAR ROSHID 710872C 32 0 0 05-Apr-2006 0 1 165.0 56.0 1.61 46.86 61.4
24 TASHI NAMGAR 752858C 21 0 0 12-Apr-2006 0 1 166.0 55.0 1.61 46.45 62.3
25 RINCHEN DEMA 786941C 23 0 0 18-Apr-2006 0 4 155.0 45.0 1.40 38.71 52.4
26 NOHRO R.C.REV. 745107C 61 0 0 19-Apr-2006 0 1 161.0 68.0 1.72 51.97 57.8
27 JYOTIRANI PANDA 765102C 35 1 0 26-Apr-2006 0 1 152.0 57.0 1.53 40.18 48.7
28 MIR MOBARAK ALI 789866C 30 0 0 02-May-2006 0 1 156.0 56.0 1.55 45.11 53.3
29 RAJ KUMAR RAWANI 750502C 24 0 0 03-May-2006 0 1 167.0 60.0 1.67 49.48 63.2
30 SHIVA KUMAR RAI 785959C 52 0 0 09-May-2006 0 1 156.0 48.0 1.45 40.68 53.3
31 MD. ZAKERHULA 780946C 25 0 0 11-May-2006 0 1 158.0 55.0 1.55 44.99 55.1
32 TUHINA SAHA 992012A 24 1 0 16-May-2006 0 1 163.0 50.0 1.52 39.57 56.1
33 RINCHEN WANGDI 802994C 34 0 0 17-May-2006 0 2 164.0 61.0 1.66 49.39 60.5
34 LALRAM DINA 817458C 32 0 0 30-May-2006 0 2 170.0 69.0 1.80 54.81 65.9
35 RAJIB BHUYAN 808528C 23 0 0 31-May-2006 0 2 177.0 61.0 1.76 51.90 72.3
36 BABITA 809363C 34 1 0 06-Jun-2006 0 4 153.0 57.0 1.54 40.45 49.4
sno name hospnum age sex race dotx cada ims ht wt bsa lbw idbw
37 SUSHIL KUMAR JAIN 917688 51 0 0 07-Jun-2006 0 2 170.0 69.0 1.80 54.81 65.9
38 PRANNATH PAUL 762896C 42 0 0 08-Jun-2006 0 2 155.0 52.0 1.49 42.79 52.4
39 RAHUL TRIPATI 784896C 16 0 0 14-Jun-2006 0 4 178.0 70.0 1.87 57.20 73.2
40 HARIBABU K., 129520B 39 0 0 21-Jun-2006 0 2 178.0 124.0 2.39 74.28 73.2
41 SATISH RAJ 545944C 23 0 0 22-Jun-2006 0 4 174.0 66.0 1.80 54.18 69.6
42 SUKKUR SHEIK 780000C 35 0 0 27-Jun-2006 0 2 165.0 61.0 1.67 49.61 61.4
43 SAILESH PRADHAN 814469C 35 0 0 28-Jun-2006 0 2 167.0 73.0 1.82 55.84 63.2
44 MD. ABDUL M SARKAR 729320C 26 0 0 05-Jul-2006 0 2 162.0 50.0 1.51 42.81 58.7
45 AJAY KUMAR (CAD) 766235C 31 0 0 05-Jul-2006 1 2 172.0 58.0 1.68 49.25 67.7
46 SEKAR E. (CAD) 839209C 45 0 0 05-Jul-2006 1 2 167.0 82.5 1.92 59.51 63.2
47 NAND K SARKAR 818426C 41 0 0 11-Jul-2006 0 2 175.0 74.0 1.89 58.51 70.5
48 INDU DEVI 826599C 40 1 0 12-Jul-2006 0 2 153.0 51.0 1.47 38.13 49.4
49 PRIYAVASANTH 832437C 17 0 0 19-Jul-2006 0 2 161.0 68.0 1.72 51.97 57.8
50 SHAILENDERA N SINGH 664575C 42 0 0 26-Jul-2006 0 4 172.0 57.0 1.67 48.64 67.7
51 G RAMNARAYAN REDY 844133C 27 0 0 02-Aug-2006 0 1 172.0 68.0 1.80 54.79 67.7
52 CHIRU KUMAR DEURI 451891C 18 0 0 08-Aug-2006 0 4 170.0 49.0 1.56 43.27 65.9
53 SANDHYA PANDEY 451334C 30 1 0 17-Aug-2006 0 4 153.0 46.0 1.40 35.84 49.4
54 GAURI PRASAD 826588C 34 0 0 22-Aug-2006 0 1 163.0 55.0 1.58 45.93 59.6
55 MD. SHAJADA SELIM 853273C 44 0 0 23-Aug-2006 0 2 179.0 83.0 2.02 63.78 74.1
56 PREM SAGAR CHAPLA 643990C 52 0 0 24-Aug-2006 0 4 167.0 68.0 1.76 53.58 63.2
57 JOGESH BARLA 672933C 56 0 0 30-Aug-2006 0 4 163.0 55.0 1.58 45.93 59.6
58 R P SINGH 851278C 21 0 0 31-Aug-2006 0 2 170.0 60.0 1.69 50.06 65.9
59 KHAIDEM KULBATI 767100C 31 1 0 05-Sep-2006 0 4 161.0 65.0 1.69 45.43 54.8
60 BISWAJIT BAIG 500081C 23 0 0 12-Sep-2006 0 3 173.0 48.0 1.56 42.95 68.7
61 DAWMA 886783C 48 0 0 26-Sep-2006 0 4 169.0 75.0 1.86 57.29 65.0
62 MAZNUR RAHMAN 894131C 31 0 0 27-Sep-2006 0 4 185.0 64.0 1.85 55.08 79.5
63 KAMALA DUNGAL 830515C 33 1 0 04-Oct-2006 0 4 151.0 48.0 1.41 36.40 48.1
64 SARIKA PATWA 792569C 26 1 0 05-Oct-2006 0 4 154.0 51.0 1.47 38.34 50.1
65 PRASENJIT CHOUDRY 732071c 29 0 0 12-Oct-2006 0 3 174.0 60.0 1.72 50.78 69.6
66 NURUL ISLAM 895598C 21 0 0 18-Oct-2006 0 3 160.0 54.0 1.55 44.82 56.9
67 LALRINTLUANGI 882084C 36 1 0 24-Oct-2006 0 4 159.0 64.0 1.66 44.50 53.4
68 JOSELYN C KR 879970C 58 0 0 26-Oct-2006 0 2 161.0 51.0 1.52 43.26 57.8
69 KAPTHIANGA 833825C 56 0 0 02-Nov-2006 0 4 163.0 54.0 1.57 45.35 59.6
70 PREMA RAJAN 412195C 53 1 0 07-Nov-2006 0 4 158.0 65.0 1.66 44.50 52.7
71 EBAM ZIRDO 893555C 43 0 0 08-Nov-2006 0 4 165.0 60.0 1.66 49.07 61.4
72 LALLIANZANI 846938C 49 1 0 09-Nov-2006 0 4 152.0 54.0 1.49 39.10 48.7
sno name hospnum age sex race dotx cada ims ht wt bsa lbw idbw
73 NIRMAL KUMAR 739666C 20 0 0 14-Nov-2006 0 2 171.0 59.0 1.69 49.66 66.8
74 LALRIMNAWMA 315714C 47 0 0 15-Nov-2006 0 2 172.0 69.5 1.82 55.55 67.7
75 JASIMUDDIN 867177C 26 0 0 21-Nov-2006 0 2 174.0 65.0 1.78 53.64 69.6
76 MD. AYUB SIKDER 880480C 42 0 0 22-Nov-2006 0 4 169.0 57.0 1.65 48.14 65.0
77 LIANZUALA 429074C 50 0 0 23-Nov-2006 0 2 178.0 64.0 1.80 53.85 73.2
78 DEBASISH PAL 768978C 20 0 0 29-Nov-2006 0 3 171.0 51.0 1.59 44.71 66.8
79 RAYMAND R PANNA 507523C 33 0 0 05-Dec-2006 0 3 165.0 65.0 1.72 51.64 61.4
80 AJAY KUMAR 925604C 22 0 0 07-Dec-2006 0 4 166.0 60.0 1.67 49.28 62.3
81 SUMAN DAS 772053C 33 0 0 12-Dec-2006 0 4 148.0 47.0 1.38 38.79 46.0
82 SANGAM LEKI 905118C 22 0 0 19-Dec-2006 0 4 162.0 49.0 1.50 42.19 58.7
83 UMESH 936347C 20 0 0 21-Dec-2006 0 4 174.0 59.0 1.71 50.18 69.6
84 RAJESH JAISWAL 801482C 34 0 0 02-Jan-2007 0 4 165.0 75.0 1.82 56.05 61.4
85 INDRANI.R. 897856B 58 1 0 05-Jan-2007 1 4 157.0 66.0 1.67 44.47 52.1
86 TAHERA BEGUM 109325A 51 1 0 05-Jan-2007 1 4 156.0 67.0 1.67 44.39 51.4
87 JEYANTHI.C. 294137C 36 1 0 16-Jan-2007 0 4 151.0 52.0 1.46 38.09 48.1
88 MOHD RAFE.M.S. 868376C 27 0 0 17-Jan-2007 0 4 174.0 60.0 1.72 50.78 69.6
89 KHAJA HUSSAIN.S.P. 505466C 23 0 0 18-Jan-2007 0 4 155.0 51.0 1.48 42.24 52.4
90 RAJESWAR SINGH 944488C 48 0 0 25-Jan-2007 0 4 170.0 62.0 1.72 51.17 65.9
91 VIOLA NILI MASSEY 327707C 34 1 0 30-Jan-2007 0 4 151.0 46.5 1.40 35.72 48.1
92 VANLALRAMHLUNI 934776C 42 1 0 31-Jan-2007 0 4 158.0 59.5 1.60 42.68 52.7
93 RAGEENA VARGHESE 904754C 17 1 0 01-Feb-2007 0 4 162.0 62.0 1.66 44.66 55.4
94 JNAN R PANIGRAHI 960631C 26 0 0 13-Feb-2007 0 4 171.0 54.5 1.63 46.95 66.8
95 SHAJI MATHEW 870996C 43 0 0 15-Feb-2007 0 4 168.0 67.5 1.77 53.59 64.1
96 SANGEY REMA 854890C 20 1 0 20-Feb-2007 0 4 150.0 42.0 1.33 33.34 47.4
97 BUDHAN KONWAR 802251C 35 0 0 21-Feb-2007 0 2 166.0 56.5 1.62 47.32 62.3
98 VENKATARAMANA.C. 948589C 30 0 0 22-Feb-2007 0 4 165.0 64.0 1.70 51.14 61.4
99 HEMRAJ MANGHATE 938462C 45 0 0 27-Feb-2007 0 4 168.0 63.0 1.72 51.30 64.1
100 KHIMAN BARAL 844870C 18 0 0 01-Mar-2007 0 4 155.0 48.0 1.44 40.52 52.4
101 ANIL KUMAR GUPTA 917947C 52 0 0 06-Mar-2007 0 4 163.0 62.0 1.67 49.68 59.6
102 LAXMI B 261315C 37 1 0 08-Mar-2007 0 4 150.0 69.0 1.64 42.51 47.4
103 HEMANT KR SINGH 954815C 31 0 0 13-Mar-2007 0 4 165.0 63.0 1.69 50.64 61.4
104 UGYENLA 968357C 41 0 0 14-Mar-2007 0 2 165.0 74.0 1.81 55.65 61.4
105 LALNUHLIRI 969968C 38 1 0 22-Mar-2007 0 4 148.0 57.0 1.50 39.04 46.1
106 DASHO T GYELSHEN 506636C 54 0 0 27-Mar-2007 0 6 168.0 67.0 1.76 53.34 64.1
107 KAVITHA KUMARI 351294C 23 1 0 28-Mar-2007 0 3 160.0 53.0 1.54 40.47 54.1
108 TSHERING WANGMO 968354C 37 1 0 29-Mar-2007 0 4 149.0 49.0 1.41 36.42 46.7
sno name hospnum age sex race dotx cada ims ht wt bsa lbw idbw
109 FAZLUL KARIM SUMON 874371C 29 0 0 03-Apr-2007 0 4 175.0 69.0 1.84 56.00 70.5
110 CHEWANG GOMDAR 343021B 54 0 0 04-Apr-2007 0 4 152.0 56.0 1.52 44.23 49.6
111 MOU CHAKRABORTHY 780879C 27 1 0 05-Apr-2007 0 3 148.0 53.0 1.45 37.73 46.1
112 MOHD SORHAB ALI 978766C 33 0 0 10-Apr-2007 0 4 168.0 62.0 1.70 50.77 64.1
113 NAND KISHORE MURMU 329734C 22 0 0 11-Apr-2007 0 4 169.0 55.5 1.63 47.25 65.0
114 WANGDUP SHERPA 826141C 19 0 0 12-Apr-2007 0 4 164.0 54.0 1.58 45.52 60.5
115 SUBRAMANI.P 994363C 33 0 0 17-Apr-2007 0 4 165.0 70.0 1.77 53.96 61.4
116 SAYAN DUTTA 830544C 17 0 0 18-Apr-2007 0 4 150.0 44.5 1.36 37.68 47.8
117 ANANDA C NAYAK 647140B 48 0 0 19-Apr-2007 0 4 173.0 48.5 1.57 43.29 68.7
118 KISHORE GURUNG 931465C 48 0 0 24-Apr-2007 0 4 154.0 60.0 1.58 46.57 51.4
119 CHANDAN RAJAK 973475C 21 0 0 26-Apr-2007 0 4 155.0 49.0 1.45 41.11 52.4
120 KAUSHIK ROY 985466C 29 0 0 01-May-2007 0 3 162.0 64.5 1.69 50.66 58.7
121 ASMA KALEEL 276802C 21 1 0 03-May-2007 0 4 156.0 60.0 1.59 42.31 51.4
122 JATINDRA MOHAPATRA 987146C 36 0 0 10-May-2007 0 4 180.0 67.0 1.85 55.97 75.0
123 HELAL AHMED 964470C 26 0 0 15-May-2007 0 4 171.0 54.0 1.63 46.64 66.8
124 MD HABILUDDIN 789397C 30 0 0 16-May-2007 0 2 153.0 47.5 1.42 39.91 50.5
125 CHANDRAKANTA D 993435C 44 1 0 23-May-2007 0 4 161.0 64.0 1.67 45.09 54.8
126 DIPA DUTTA 984100C 39 1 0 24-May-2007 0 3 150.0 47.5 1.40 35.98 47.4
127 VANLAL RATLUNGA 005572D 35 0 0 05-Jun-2007 0 4 165.0 58.0 1.63 47.98 61.4
128 AMRITA GHOI 709096B 16 1 0 07-Jun-2007 0 6 148.0 43.5 1.34 33.76 46.1
129 MD. ABDUR RAQUIB 418138C 41 0 0 13-Jun-2007 0 4 167.0 56.0 1.62 47.21 63.2
130 TARUN KUMAR 890225C 25 0 0 14-Jun-2007 0 4 166.0 55.0 1.61 46.45 62.3
131 LABONI PATI 937614C 15 1 0 20-Jun-2007 0 3 153.0 46.5 1.41 36.08 49.4
132 NAGAENDRA KUMAR 660957C 22 0 0 26-Jun-2007 0 4 183.0 67.0 1.87 56.54 77.7
133 DHAN BDUR. MO 029203D 40 0 0 27-Jun-2007 0 4 163.0 66.0 1.71 51.61 59.6
134 GOSTHA GOPAL 022399D 25 0 0 28-Jun-2007 0 4 174.0 69.0 1.83 55.77 69.6
sno name
1 JAIRUL HAQUE
2 KANU DEBNATH
3 GAYATHRI
4 RANGANATHAN
5 KRISHNA GHOSH
6 RICHARD LALNUNPUIA
7 BALMAYA DAHAL
8 MOHD MASUM
9 RAM G GANGULI
10 TSHERING TASHI
11 BIJOY PRASAD
12 PRAKASH BAIDYA
13 SAIFUL ISLAM
14 RANGARAJULU
15 CHANDRASEKAR
16 RATAN KANTI KHAR
17 LALAN KUMAR
18 GANESH KUMAR
19 SITA DEVI
20 FALAN MOLLA
21 PAVANI LAKSHMII
22 JAYANATH KR SINGHA
23 HARUNAR ROSHID
24 TASHI NAMGAR
25 RINCHEN DEMA
26 NOHRO R.C.REV.
27 JYOTIRANI PANDA
28 MIR MOBARAK ALI
29 RAJ KUMAR RAWANI
30 SHIVA KUMAR RAI
31 MD. ZAKERHULA
32 TUHINA SAHA
33 RINCHEN WANGDI
34 LALRAM DINA
35 RAJIB BHUYAN
36 BABITA
creat urea alb cysc dtpa pruria
2.3 64 4.2 3.91 18.00 321
1.6 47 4.3 2.17 40.00 80
1.3 45 4.6 2.07 75.00 266
1.3 45 4.2 1.25 32.40 746
1.1 32 4.1 1.20 79.60 116
1.9 38 4.7 2.13 57.40 195
1.1 17 4.1 1.42 80.20 150
1.1 15 4.3 1.20 68.00 200
1.5 37 3.9 1.82 33.90 146
0.9 27 4.2 1.23 103.00 109
1.8 58 4.0 2.63 19.50 496
1.4 30 3.9 2.00 46.00 113
1.3 29 4.4 1.61 66.50 151
1.4 44 4.3 1.99 30.00 233
1.7 44 4.0 2.67 32.00 166
1.1 24 3.8 1.50 29.00 543
1.7 97 3.0 3.24 35.00 81
1.2 39 4.4 1.71 75.00 157
1.5 42 3.8 2.25 22.00 63
1.8 62 3.2 1.51 33.00 166
1.0 26 4.2 1.12 56.70 52
1.0 31 3.9 1.88 74.00 99
1.3 22 4.2 1.46 48.00 110
1.1 24 4.4 1.35 55.00 89
0.8 15 4.3 1.12 112.00 64
1.0 37 3.7 1.40 47.00 53
1.2 44 3.6 2.31 106.00 86
1.1 25 4.2 1.44 38.00 157
1.5 39 4.0 2.31 44.00 112
1.3 28 4.1 1.93 37.00 415
1.4 38 4.0 2.14 49.00 335
1.1 37 4.3 1.67 84.00 104
1.2 42 4.2 1.53 39.20 81
1.8 45 4.4 2.63 27.00 261
1.3 38 4.1 1.85 55.00 92
1.1 34 4.0 1.48 72.00 208
sno name
37 SUSHIL KUMAR JAIN
38 PRANNATH PAUL
39 RAHUL TRIPATI
40 HARIBABU K.,
41 SATISH RAJ
42 SUKKUR SHEIK
43 SAILESH PRADHAN
44 MD. ABDUL M SARKAR
45 AJAY KUMAR (CAD)
46 SEKAR E. (CAD)
47 NAND K SARKAR
48 INDU DEVI
49 PRIYAVASANTH
50 SHAILENDERA N SINGH
51 G RAMNARAYAN REDY
52 CHIRU KUMAR DEURI
53 SANDHYA PANDEY
54 GAURI PRASAD
55 MD. SHAJADA SELIM
56 PREM SAGAR CHAPLA
57 JOGESH BARLA
58 R P SINGH
59 KHAIDEM KULBATI
60 BISWAJIT BAIG
61 DAWMA
62 MAZNUR RAHMAN
63 KAMALA DUNGAL
64 SARIKA PATWA
65 PRASENJIT CHOUDRY
66 NURUL ISLAM
67 LALRINTLUANGI
68 JOSELYN C KR
69 KAPTHIANGA
70 PREMA RAJAN
71 EBAM ZIRDO
72 LALLIANZANI
creat urea alb cysc dtpa pruria
3.2 73 3.9 5.55 14.00 1,150
1.1 29 4.3 1.69 49.00 155
1.3 27 4.1 1.62 36.00 228
1.2 34 3.9 2.37 28.00 107
1.8 42 4.2 2.54 42.00 313
1.5 62 4.0 1.99 37.00 1,600
1.7 33 4.4 2.06 31.00 105
1.0 24 4.3 1.15 80.00 126
1.1 28 4.1 2.11 45.00 162
1.3 35 4.5 2.06 11.00 382
1.4 27 4.5 1.81 34.60 495
0.9 27 4.2 1.29 80.00 97
1.4 21 4.2 2.30 23.00 120
1.1 28 4.4 1.39 65.00 262
1.4 35 4.5 1.95 33.50 213
1.3 43 4.5 2.00 84.00 2,600
1.1 25 4.4 1.13 63.00 58
0.8 24 4.6 1.04 76.60 108
1.0 19 4.5 1.28 29.00 140
1.3 43 4.3 2.60 37.00 237
0.9 33 4.4 1.30 58.00 109
1.5 32 4.2 1.69 65.00 75
0.9 27 4.3 1.23 46.00 83
1.4 33 4.4 2.23 41.00 124
1.4 29 4.2 1.70 33.00 530
1.5 24 4.5 1.86 32.00 136
1.4 26 4.0 1.64 53.00 106
1.0 26 4.3 1.20 97.00 148
1.1 26 3.9 1.31 68.00 104
1.1 37 4.0 1.42 100.00 134
0.9 25 4.4 1.35 75.00 58
1.5 53 3.3 1.95 83.40 143
1.3 32 4.1 1.45 57.00 87
1.1 31 3.9 1.31 53.00 60
1.4 44 4.6 1.36 55.00 69
0.9 28 3.7 1.20 113.00 49
sno name
73 NIRMAL KUMAR
74 LALRIMNAWMA
75 JASIMUDDIN
76 MD. AYUB SIKDER
77 LIANZUALA
78 DEBASISH PAL
79 RAYMAND R PANNA
80 AJAY KUMAR
81 SUMAN DAS
82 SANGAM LEKI
83 UMESH
84 RAJESH JAISWAL
85 INDRANI.R.
86 TAHERA BEGUM
87 JEYANTHI.C.
88 MOHD RAFE.M.S.
89 KHAJA HUSSAIN.S.P.
90 RAJESWAR SINGH
91 VIOLA NILI MASSEY
92 VANLALRAMHLUNI
93 RAGEENA VARGHESE
94 JNAN R PANIGRAHI
95 SHAJI MATHEW
96 SANGEY REMA
97 BUDHAN KONWAR
98 VENKATARAMANA.C.
99 HEMRAJ MANGHATE
100 KHIMAN BARAL
101 ANIL KUMAR GUPTA
102 LAXMI B
103 HEMANT KR SINGH
104 UGYENLA
105 LALNUHLIRI
106 DASHO T GYELSHEN
107 KAVITHA KUMARI
108 TSHERING WANGMO
creat urea alb cysc dtpa pruria
1.8 57 4.0 2.68 20.00 184
1.0 24 4.3 1.34 54.00 69
1.4 31 4.4 1.55 59.00 220
1.1 34 4.3 1.45 46.00 68
1.3 27 4.3 1.58 43.00 392
1.2 34 4.6 1.23 81.00 597
1.2 25 4.3 1.82 49.00 258
1.3 24 4.8 1.60 34.00 382
1.1 25 4.4 1.31 82.00 171
1.0 25 4.9 1.50 43.00 213
1.2 20 5.0 1.44 69.00 89
1.8 40 4.5 2.47 21.00 155
1.2 40 3.5 1.52 24.00 72
1.0 30 4.0 1.47 63.00 234
0.9 23 3.8 1.46 41.00 90
1.4 38 4.5 1.91 32.00 481
1.2 29 3.3 1.66 20.00 145
0.9 29 4.0 1.29 44.00 180
0.9 18 4.1 1.17 29.00 229
0.8 21 4.3 0.98 74.00 164
0.9 19 4.0 0.96 71.00 160
1.1 32 4.2 1.38 57.00 164
1.2 40 4.7 0.97 54.50 191
0.7 28 4.1 1.07 69.00 48
1.5 34 4.2 2.23 35.00 383
1.2 24 4.0 1.29 53.00 146
1.3 24 4.3 2.05 21.50 131
1.0 24 4.6 1.20 60.90 240
1.0 37 4.4 1.26 40.60 87
0.8 21 4.1 1.24 37.60 187
1.4 35 4.8 1.60 35.00 188
1.3 21 4.4 1.60 30.00 127
0.8 20 3.9 0.95 89.40 147
1.0 33 4.7 1.06 61.20 79
0.8 17 4.6 1.22 60.30 178
0.7 31 4.5 0.89 56.40 85
sno name
109 FAZLUL KARIM SUMON
110 CHEWANG GOMDAR
111 MOU CHAKRABORTHY
112 MOHD SORHAB ALI
113 NAND KISHORE MURMU
114 WANGDUP SHERPA
115 SUBRAMANI.P
116 SAYAN DUTTA
117 ANANDA C NAYAK
118 KISHORE GURUNG
119 CHANDAN RAJAK
120 KAUSHIK ROY
121 ASMA KALEEL
122 JATINDRA MOHAPATRA
123 HELAL AHMED
124 MD HABILUDDIN
125 CHANDRAKANTA D
126 DIPA DUTTA
127 VANLAL RATLUNGA
128 AMRITA GHOI
129 MD. ABDUR RAQUIB
130 TARUN KUMAR
131 LABONI PATI
132 NAGAENDRA KUMAR
133 DHAN BDUR. MO
134 GOSTHA GOPAL
creat urea alb cysc dtpa pruria
1.2 20 4.4 1.51 42.60 143
1.5 85 4.3 2.15 17.40 375
0.9 26 4.2 1.00 77.70 113
1.8 50 4.5 2.34 21.30 553
2.2 110 2.6 3.75 25.00 3,100
1.8 39 4.6 1.70 33.00 163
1.8 32 4.5 1.69 19.00 400
1.1 33 4.5 1.33 59.00 93
0.8 15 4.1 1.20 74.00 262
1.0 28 4.7 0.92 47.50 95
1.0 29 4.6 1.20 77.00 480
1.2 34 4.6 1.30 57.00 109
0.9 37 4.3 1.27 43.30 121
1.6 38 4.2 2.41 24.00 221
1.2 35 4.7 1.44 45.00 218
1.1 28 4.4 1.62 97.00 117
1.1 25 4.0 1.43 41.20 150
1.2 38 4.1 1.56 58.00 144
1.3 24 4.4 1.49 49.83 297
0.8 27 4.0 1.11 72.00 150
1.2 26 4.8 1.41 53.00 163
1.0 31 4.7 1.29 59.00 330
0.9 35 5.0 1.39 75.00 254
1.4 24 5.1 1.18 49.00 215
0.9 29 4.6 1.19 91.00 136
1.5 46 4.8 1.53 62.00 107
